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ABSTRACT 
Vaccination is one of the most successful public health interventions in history, 
and is estimated to save lives of 3 million children globally each year. Ongoing 
surveillance is warranted to identify further evolution of the epidemiology of 
vaccine preventable diseases, and to evaluate the effects of vaccines provided. 
This dissertation aims to explore the impact of vaccines on disease burden, and 
effectiveness of diagnostic tools for two important infectious diseases; 
pneumonia and tuberculosis (TB).  
 The first study employed a large electronic health record data, 
Massachusetts Health Disparities Repository (MHDR), to evaluate impact of 13-
valent conjugated pneumococcal vaccine (PCV13) on all-cause pneumonia 
among children who receive primary care at Boston Medical Center (BMC). We 
extracted all-cause pneumonia cases diagnosed at both inpatient and outpatient 
  vii 
settings among children younger than 8 years of age. Using interrupted time-
series regression analysis monthly rates estimated for years after (2011–2013) 
implementation of PCV13 were compared to expected rates calculated from pre-
PCV13 era (2007–2009). The year of PCV13 introduction (2010) was excluded.  
We also extracted cases of urinary tract infection and evaluated as control 
outcome. At the end of 2013 compared to prePCV13 era, among children 
younger than 2 years of age there was a 35.3% (95% CI 5.4–65.3) reduction in 
all-cause pneumonia cases. In children with comorbidity, pneumonia declined by 
38.8% (95% CI 11.1 to 65.4) in those younger than 2 years of age, and 28.7% 
(95% CI 2.9 to 54.5) in those 2 to 8 years of age. The results of this study 
contribute to the growing body of evidence supporting the benefit of direct and 
indirect protection with conjugated vaccines, and emphasize the importance of 
high sustainable vaccine coverage rates.  
 The second and the third studies used data from the Tuberculosis 
Epidemiologic Studies Consortium (TBESC) Study-1, a 10-site collaboration of 
academic institutions and state and local TB control programs that is funded and 
administered by the Division of Tuberculosis Elimination at the Centers for 
Disease Control and Prevention (CDC). The second study evaluated the impact 
of Bacille Calmette Guérin (BCG) vaccination, which continues to be the only 
vaccine available for prevention of TB, on tuberculin skin testing (TST) results. 
Using the data collected TBESC Study-1 between September 2012 and 
September 2014, we examined the association between BCG vaccination and 
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TST positivity. Logistic regression models were used to calculate adjusted 
prevalence ratios (PR) and 95% confidence intervals (CI). Prior BCG vaccination 
had no impact on the TST results once adjusted for history of household contacts 
(adjusted PR 1.0, 95% CI 0.4–1.5). The results of this study add further evidence 
that BCG vaccination has little impact on TST results in children, particularly in 
older age groups. 
The third study examined the cost-effectiveness of three different 
screening strategies compared to no screening for latent tuberculosis infection 
(LTBI) in a population with high proportion of foreign-born individuals who have 
different risk levels for developing TB. In this study, everyone was tested with 
using all available tools for LTBI: TST, and interferon-gamma release assays 
(IGRAs) during their enrollment visit. We used decision tree analysis and Markov 
models to compare TST only, IGRA only, TST followed by IGRA among those 
who were TST positive, and no screening strategies. Regardless of the 
assumptions and tests used, screening provided better health outcomes such as 
less TB cases and less TB related mortality compared to no screening. The 
incremental cost-effectiveness ratio (ICER) of TST followed by IGRA compared 
to no screening was $75,094 per QALY gained. The results of this study suggest 
that prioritizing certain groups for targeted LTBI screening such as foreign-born 
individuals, and using TST followed by IGRA can maximize the impact of public 
health resources allocated to eradicate TB in the U.S.  
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The findings from these studies will contribute to the further understanding 
of the impact of the vaccines and the changing epidemiology of vaccine-
preventable diseases providing more insight to formulate new strategies to 
improve overall health of children. 
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1. INTRODUCTION 
 
 Vaccination has greatly reduced the burden of many infectious diseases 
such as polio, diphtheria, tetanus worldwide.1–3 In the United States, widespread 
childhood vaccination has decreased most vaccine-preventable childhood 
diseases by more than 95 percent since 1980s.4 The overwhelming public health 
success of vaccines also contributed to the evolution of population level 
dynamics of the vaccine preventable diseases, and ongoing surveillance is 
warranted to identify further effects of vaccines provided. Continuing attention is 
also needed to ensure that accurate methods are used for diagnosis of infectious 
diseases among populations with widespread vaccination coverage as sensitivity 
and specificity of diagnostic tools can be different with changing epidemiology in 
vaccine era.  
 Conjugated pneumococcal vaccine (PCV) provides immunity against 
Streptococcus pneumoniae which is recognized as the primary bacterial 
pathogen of pneumonia in all age groups.5–6 The first conjugated 7-valent 
pneumococcal conjugate vaccine (PCV7) was added to the United States infant 
immunization schedule in the year 2000, and by 2009, a 43% decline in all-cause 
pneumonia among children was observed.7 However, along with the decline in 
pneumococcal disease caused by PCV7 serotypes, an increase in disease 
attributed to serotypes not included in PCV7 (replacement disease) was 
observed.8,9 This resulted in the introduction of a second generation, 13-valent 
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conjugate vaccine (PCV13) targeting six additional serotypes in 2010.10 Because 
serotypes 1, 3, 7F, and 19A were the most predominant in documented 
pneumococcal pneumonia in children and these serotypes were included in 
PCV13, a strong additional impact of this new PCV on the disease burden was 
expected but not yet demonstrated. In addition, despite broad vaccine uptake 
bacterial pneumonia remains disproportionately more frequent in urban, minority 
children including greater morbidity and mortality.6,11 We propose to assess the 
burden of pneumonia in children in the BMC health network and to evaluate the 
impact of PCV13 introduction on disease incidence and excess risk in children 
with at-risk and high-risk conditions as defined by 2012 Report of The Committee 
on Infectious Diseases of the American Academy of Pediatrics (AAP)12 and 2013 
recommendations by the Advisory Committee on Immunization Practices.13  
 Tuberculosis (TB) is caused by Mycobacterium tuberculosis (MTB), and 
remains a major global health problem with an estimated 9 million new cases and 
1.5 million deaths reported worldwide in 2013.14 Persons with latent tuberculosis 
infection (LTBI) have a 10% risk of developing overt disease during their 
lifetime.15 An estimated 11 million people living in the US have LTBI, and 
reactivation of LTBI accounts for the majority of active TB cases. Therefore, a 
critical component of domestic TB prevention and control is the identification and 
treatment of persons with LTBI who are at the highest risk of progression to 
active TB disease. Screening with TST is an important tool for the evaluation of 
contacts and suspected cases of TB particularly in resource limited settings, 
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however is reputed to be falsely positive due to previous BCG vaccination.14–16 
Two new interferon-gamma release assays (IGRAs); QuantiFERON-TB Gold In-
Tube (QFT) and the T-SPOT.TB (T-Spot) use specific antigens produced by 
ESAT-6 and CFP-10 gene families not found in the BCG vaccine or in most 
environmental mycobacteria making IGRAs highly specific for the diagnosis of 
active and latent TB. ,16,17,19 
 The goal of this dissertation is to further our understanding of the impact of 
vaccines on disease burden and effectiveness of diagnostic tools for two 
important infectious diseases; pneumonia and TB. The first study uses data from 
a large electronic health record data, Massachusetts Health Disparities 
Repository (MHDR) and an interrupted time-series regression analysis to 
evaluate impact of 13-valent conjugated pneumococcal vaccine (PCV13) on all-
cause childhood pneumonia among children who receive primary care at Boston 
Medical Center (BMC). The second and the third studies used data from the 
Tuberculosis Epidemiologic Studies Consortium (TBESC) Study-1, a 10-site 
collaboration of academic institutions and state and local TB control programs 
that is funded and administered by the Division of Tuberculosis Elimination at the 
Centers for Disease Control and Prevention (CDC). The second study evaluated 
the impact of Bacille Calmette Guérin (BCG) vaccination, which continues to be 
the only vaccine available for prevention of TB, on tuberculin skin testing (TST) 
results. The third study examined the cost-effectiveness of three different 
screening strategies compared to no screening for latent tuberculosis infection 
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(LTBI) in a population with high proportion of foreign-born individuals who have 
different risk levels for developing TB. 
 The following chapters are presented in the format of a manuscript 
appropriate for submission to a peer-reviewed journal. Each section contains its 
own specific introduction, methods, results, discussion, and references sections. 
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2  IMPACT OF 13-VALENT PNEUMOCOCCAL VACCINE ON 
CHILDHOOD ALL-CAUSE PNEUMONIA AT AN URBAN HOSPITAL 
2.1  ABSTRACT  
 Pneumonia is a major cause of childhood mortality with a disproportionally 
high burden among in urban, minority children. Streptococcus pneumoniae is 
recognized as a leading bacterial cause of pneumonia. The objective of this 
study was to define the disease burden of pneumonia among children   following 
implementation of 13-valent conjugated pneumococcal vaccine (PCV13) in urban 
settings in Boston, U.S., and to quantify increased pneumonia risk among 
children with comorbid conditions.  Data from the Massachusetts Health 
Disparities Repository were analyzed via interrupted time-series regression 
analysis using rates of all-cause pneumonia before and after implementation of 
PCV13 in Massachusetts as the main outcome. At the end of 2013 compared to 
prePCV13 era, among children younger than 2 years of age there was a decline 
of 176.4 pneumonia cases (95% CI 26.7 to 326.1) per 10,000, corresponding to a 
35.3% (95% CI 5.4–65.3) reduction. The difference between the number of 
observed versus expected pneumonia cases (“averted cases”) increased over 
time during the post-PCV13-era. In children with comorbidity, pneumonia 
declined by 38.8% (95% CI 11.1 to 65.4) in those younger than 2 years of age 
and 28.7% (95% CI 2.9 to 54.5) in those 2 to 8 years of age. The reduction in all-
cause pneumonia rates provides an estimate of the burden of vaccine 
  9 
preventable pneumonia cases. Our results contribute to the growing body of 
evidence supporting the benefit of indirect protection with conjugated vaccines 
and emphasize the importance of high sustainable vaccine coverage rates.  
  10 
2.2 INTRODUCTION 
 
 Global child deaths have declined from 12.6 million to 6.6 million over the 
last two decades,1,2 and increasing access to immunization, specifically for 
younger children, is believed to account for much of this reduction.3 Annual 
global mortality rates for children under 5 years of age, the main target age group 
for the majority of childhood immunizations, has declined 28% from 90 deaths 
per 1,000 live births in 1990 to 65 deaths per 1,000 live births in 2008.4 In the 
United States (U.S.), widespread childhood vaccination has decreased most 
vaccine-preventable childhood diseases by more than 95 percent during the 20th 
century. However, even though more children are immunized than ever before as 
a result of many consortiums similar to Global Alliance for Vaccines and 
Immunization 5, one of the main targets of all vaccine programs, pneumonia, 
remains a cause of substantial morbidity and mortality in all age groups, 
accounting for 3–18% of all childhood hospital admissions.6 Pneumonia claimed 
the lives of 1.3 million children in 2011, representing 18% of all child deaths 
worldwide.7,8 
 Streptococcus pneumoniae is recognized as a leading bacterial cause of 
pneumonia,7,9,10 and accounts for 17–44% of pneumonia-related hospital 
admissions in children.11 One of the most successful vaccines in the current 
routine childhood immunization program is conjugated pneumococcal vaccine 
(PCV), which is widely used worldwide and provides immunity against invasive 
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pneumococcal diseases such as pneumonia.7,9 The first conjugated 7-valent 
pneumococcal conjugate vaccine (PCV7) including serotypes 4, 6B, 9V, 14, 18C, 
19F, and 23F was added to the U.S. infant immunization schedule in 2000. By 
2009, a 43% decline in all-cause pneumonia among U.S. children was 
observed.12  
 However, along with the decline in overall pneumococcal disease caused 
by PCV7 serotypes, an increase in disease, particularly complicated pneumonia 
13,14 attributed to serotypes not included in PCV7 (i.e., replacement disease) has 
been observed. 15,16 In 2010 this resulted in the introduction of a second 
generation 13-valent conjugate vaccine (PCV13) targeting six additional 
serotypes (1, 3, 5, 6A, 7F, and 19A).17 Because four of the serotypes included in 
the updated vaccine formulation (1, 3, 7F, and 19A) were responsible for the 
majority of remaining pneumococcal pneumonia in children, a strong additional 
impact on disease burden was expected, but has not yet been demonstrated. In 
addition, despite broad vaccine uptake, bacterial pneumonia remains 
disproportionately more frequent in urban, minority children. Whether the impact 
of PCV13 on pneumonia burden in this group of children differs from the general 
target population is unknown.7,8  
 The objective of this study was to define the disease burden of all-cause 
pneumonia in the post-PCV13 era compared to the pre-PCV13 era in urban 
setting in the U.S. and to quantify increased pneumonia risk among children with 
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comorbid conditions compared with healthy children in order to formulate new 
strategies for prevention of childhood pneumonia. 
2.3  METHODS 
 
2.3.1. Study Population 
 The study population included all children younger than 8 years of age 
who had at least one well child visit (WCV) at Boston Medical Center (BMC) 
between 01/01/2007 and 12/31/2013. Pneumonia was ascertained within the 12 
months following a randomly selected WCV for each individual. Follow up time 
ended at the earlier of time of diagnosis of pneumonia or 12 months of follow up 
(Figure 2.1).   
2.3.2. Data Collection  
 Data for this study was gathered from electronic medical record included 
in the Massachusetts Health Disparities Repository (MHDR), which is maintained 
at the Boston University School of Medicine, Boston, MA. For over a decade, 
BMC — the largest safety-net hospital in New England — and its affiliated 
Community Health Centers (CHCs) have successfully used a network of 
electronic health record 18 systems that has recently been linked to administrative 
and financial data to create the MHDR. The MHDR contains over 700 million 
clinical data elements (demographics, visit history, diagnoses, medications, 
immunization history, etc.) for over 1.4 million individuals including 80,000 
primary care patients less than 18 years of age. MHDR data are de-identified, 
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contain actual clinical records rather than just certain codes, and have already 
been the source of data for several studies.19,20  
2.3.3. Definition of Variables 
Exposure 
 The primary exposure was time period in relation to implementation of 
PCV13 into the routine childhood immunization schedule in the U.S. The pre-
PCV13 era was defined as the period beginning on January 1, 2007 and ending 
on December 31, 2009, and the post-PCV13 era was defined as the period 
beginning on January 1, 2011 and ending on December 31, 2013.  
 Outcomes 
 The primary study outcome was inpatient and outpatient episodes of all-
cause pneumonia that included all cases of pneumonia within 12 months 
following the randomly selected BMC primary care visit identified by International 
Classification of Diseases 9th version (ICD-9) codes used for primary and/or 
secondary diagnoses (Table 1.1). These ICD-9 codes have been validated in 
previous studies for diagnosis of all-cause pneumonia both in pediatric and adult 
populations.12,21–23 
 Urinary tract infections, common infectious conditions in early childhood, 
were defined using ICD-9 codes and used as control outcomes for comparison 
purposes. 
Covariates 
  Sociodemographic factors that were assessed in this study included: age, 
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race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, Asian, other), 
primary language (English/other), and health-insurance type (private, non-
private). Age was defined using date of birth ± 30 days of actual dates of birth (as 
per HIPAA restrictions) and was categorized into five groups as; 1) <6 months, 2) 
6 <12 months, 3) 12 <24 months, 4) 24 <60 months and 5) >60 months.  
 Immunity by PCV13 vaccine was used as a surrogate of vaccine coverage 
in the source population and defined using the PCV13 vaccination history that 
was ascertained using pneumococcal vaccine/drug codes (Appendix 1). 
Presence or absence of presumed immunity (yes/no) was described as following: 
a child was categorized as “presumed immune” if the child had received an 
adequate number of PCV13 immunizations (detailed below) at least 14 days (this 
interval was the minimum amount of time necessary to generate an immune 
response24) before the outcome, and if each dose was given at least 28 days 
apart from the previous dose. Adequate number of immunization changed by age 
and was defined as following: 
1) Children <12 months of age were defined as “presumed immune” if 
they had received 2 or more PCV13 doses, and were defined as 
“presumed nonimmune” if they had received 0 or 1 PCV13 doses; 
2) Children 12 months of age or older were defined as “presumed 
immune” if they had received 3 PCV doses in first year of life OR had at 
least 1 PCV13 dose after the age of 12 months; otherwise they were 
classified as “presumed nonimmune.” 
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Presence of underlying comorbid conditions (yes/no)  considered to confer 
increased risk for invasive pneumococcal disease per American Academy of 
Pediatrics (AAP) 24 and Advisory Committee on Immunization Practices (ACIP) 25 
guidelines were assessed using ICD-9 codes as defined by Elixhauser et al.26 
These codes have been used widely to measure burden of disease with 
administrative data in other studies. 27 Underlying comorbid conditions included 
but were not limited to congenital or acquired immunodeficiency, human 
immunodeficiency virus (HIV), absent or abnormal splenic function (e.g. sickle 
cell disease, congenital or surgical asplenia), congenital or acquired 
cerebrospinal fluid leak, cochlear implant, chronic renal failure, nephrotic 
syndrome, chronic lung disease, chronic heart disease, diabetes mellitus, 
malignant neoplasms, and leukemia/lymphoma. The incidence and severity of 
pneumococcal infections are known to be higher among children with these 
conditions and AAP recommends pneumococcal immunization in this group 
independent from age.24  
We also obtained data from the Massachusetts Department of Public 
Health on state-wide influenza-like illness rates among individuals less than 18 
years of age, and included these rates in models to control for the influenza 
attack rate, severity and influenza vaccine coverage. A list of additional 
independent variables examined in the current study and ICD-9 codes used to 
define these conditions are presented in Table 1.2. 
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2.3.4. Statistical analysis  
 First, descriptive analyses were conducted by calculating the frequency 
and proportion of all-cause pneumonia cases among children younger than 8 
years of age who received primary care at BMC between 2007 and 2014 for 
each time period (pre-PCV13 era and post-PCV13 era), and within categories of 
important demographic variables (e.g.; age, ethnicity, gender, etc.), immunization 
categories, other important possible predictors of all-cause pneumonia (e.g.; 
presence of comorbid conditions, etc.). Next, incidence rates of all-cause 
pneumonia that was diagnosed at BMC which required hospitalization or was 
treated in outpatient settings were calculated by dividing the number of cases by 
exposed and unexposed person-time, where person-time was censored after the 
occurrence of the first event or at the end of the time period, whichever was 
sooner, and was expressed per 10,000 person-years.  The exposed condition 
was defined as post-PCV13 era (2011–2013), and the reference condition was 
pre-PCV13 era (2007–2009). Rate ratios and corresponding 95% confidence 
intervals (CI) were used for comparing disease burden for the post-PCV13 era to 
the pre-PCV13 era. Urinary tract infection was defined as control outcome and 
used for comparison purposes. 
 Next, we conducted stratified analyses to assess for potential 
confounding. Demographic or clinical variables that, when included in adjusted 
models, influenced unadjusted rate ratios by 10% or more were retained in later 
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models. Age was kept in all models independent from its effect on unadjusted 
rate ratios because it is a clinically important and relevant covariate for childhood 
pneumonia. Poisson regression was used to estimate the rate ratios of the 
association between all-cause pneumonia and PCV13 era adjusted for multiple 
confounders. The data were also stratified by presence of comorbidity, age (<24 
months vs. >=24 months) to further explore the possibility of effect measure 
modification (EMM) by comorbidity and age. If EMM was observed, biologic 
interaction was assessed by calculating interaction contrast to determine whether 
the independent effects approximately summed up to the total effect of both 
covariates working together by using the following formula: 
  
where R is rate of all-cause pneumonia, E is post-PCV13 era and C is the 
covariate defined as modifier. 
 Next, we fitted the monthly pneumonia case counts to an interrupted time-
series model, accounting for secular trends and state-wide influenza activity 
during study period. Segmented regression models were created with the 
following general form: 
Yt = exp (β0 + β1*(Sec) t + β2*sin(2πt /12) + β3*cos(2πt /12)+  
β4*(period) t+ β5*(ILI) t+….. 
--+--+++ +--= CECECECE RRRRContrastn Interactio
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Where Yt was the number of pneumonia cases in month t and β0 was the 
regression coefficient. β1*Sec represented the secular trends during study period. 
“β2*sin(2πt /12)” and “β3*cos(2πt /12)" adjusted for the sinusoidal seasonality 
which fits  the pattern of higher incidence during winter months, “β4*period “ 
accounted for pre- vs. post-PCV13 era, and “β5*ILI” reflected the  number of 
cases diagnosed with influenza-like-illness statewide.  
In addition, gender, study month, vaccination, and their respective 
interaction terms were included in the initial full model. The twelve months 
between April 2010 and April 2011 was considered as the burn-in period before 
the post-PCV13 era (2011-2013) and was excluded from the modeling.  
“Vaccination” was coded as “0” before April 2010, and as “1” after the burn-in 
period.  The model which minimized the Akaike information criterion (AIC), was 
chosen as the final model.  
Lastly, we estimated the number of pneumonia cases averted in the 
PCV13 era by calculating the differences between pneumonia cases in the post-
PCV13-era on the original data (“vaccine” variable coded as “1”) and predicted 
rates in the absence of PCV13 (“vaccine” variable coded as “0”) during this same 
time period.   
 In addition, given the complexity of pneumonia diagnosis, an in-depth 
chart-review of a sub-set of approximately 10% of the study population sampled 
randomly was conducted to develop a better understanding of the accuracy of 
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the data retrieval process, and the consistency of pneumonia ascertainment by 
using ICD-9 diagnoses with clinical notes included in each chart.  This 
information was used to define negative/positive predictive values in validation of 
the use of ICD-9 codes in the major dataset and in bias analysis. 
 Finally, as misclassification can be a common problem in research using 
retrospective electronic medical records, we conducted a bias analysis to assess 
the potential impact of misclassification of pneumonia and residual uncontrolled 
confounding by comorbidity on our observed results. We assumed that any 
outcome and confounder misclassification was non-differential. In other words, 
misclassification of comorbidity was assumed to be independent from pneumonia 
status, and misclassification of all-cause pneumonia was assumed to be 
independent from the PCV13-time period.  In addition, we assumed that children 
without comorbidity and pneumonia would be correctly classified as such, 
resulting in 100% specificity 
 All statistical analyses were performed within the SAS Software (SAS 
Institute Inc., SAS 9.1.3 Help and Documentation, Cary, NCS, USA), and R 
statistical and computing environment (R Foundation for Statistical Computing, 
Vienna, Austria). 
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2.4 RESULTS 
 
2.4.1 Descriptive Analyses  
 
 A total of 141,064 WCV for patients less than 8 years of age were 
identified at BMC during the study period (Figure 2.2.). The distribution of visits 
and children by age groups per year are summarized in Tables 2.3. and 2.4, 
respectively, and were similar across calendar years included in the study. In 
each year, the distribution of visits changed with the age groups but remained 
similar within the years (Table 2.4) (e.g. 34.5% of the visits in 2008 were for 24 
mo-<60 mo age group and 7.3% of the visits were for children in 6 mo-<12 mo 
age group, whereas in 2012 it was 34.8% and 6.1%, respectively). A total of 
39,071 well child visits and 30,954 unique children were included in the analysis 
(Figure 2.2). The descriptive characteristics of the study population are displayed 
in Tables 2.5. and 2.6. 
 We identified 1162 unique cases of pneumonia during the study period. 
Annual pneumonia rates for all children were 409.8, 327.4, 424.6, 381.8, 357.4, 
and 260.6 cases per 10,000 person-years in 2007, 2008, 2009, 2011, 2012 and 
2013, respectively (Figure 2.3). The average unadjusted rate of all-cause 
pneumonia during the pre-PCV13 era was 332.6 cases per 10,000 person-years 
and 75.3 cases per 10,000 person-years during the post-PCV13 era. This 
corresponds to a 17% reduction (RR 0.83, 95% CI 0.74–0.93) in all-cause 
pneumonia following the implementation of PCV13 (Table 2.7). The rate of 
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urinary tract infection, which was the negative control in this study, was similar 
between the pre-PCV13 (162.0; 95% CI 144.3 to 181.4) and post-PCV13 era 
(148.8; 95% CI 132.7 to 166.2 per 10,000 person-years)(rate difference -13.26, 
95% CI -38.18 to 11.66) (Figure 2.4). 
2.4.2 Stratified Analyses  
 
 The results of all stratified analyses are presented in Table 2.8. The crude 
associations in the stratified analyses indicate that in the post-PCV13-era, the 
rate of all-cause pneumonia declined substantially with a crude rate ratio of 0.83 
(95% CI 0.74–0.93).  
 The adjusted rate ratios for the association between PCV13-era and all-
cause pneumonia in urban Boston children younger than 8 years old after 
controlling alone for gender, age, race, immunization status, presence of 
comorbidity and passive smoking were 0.83 (95% CI 0.75–0.92), 0.83 (95%CI 
0.47–0.93), 0.88 (95% CI 0.79–0.97), 0.82 (95%CI 0.74–0.90), 0.83 (95%CI 
0.75–0.92) and 0.83 (95% CI 0.75–0.91), respectively. None of the tested 
variables were defined as confounders using the approach detailed in the 
methods sections.  
  The stratified analyses also revealed that gender, comorbidity and age 
were important effect modifiers of the association between PCV13-era and all-
cause pneumonia. For example, among girls, all-cause pneumonia rates 
declined 28% [RR 0.72 (95% CI 0.62–0.82)], whereas among boys this decline 
was estimated as 4% [RR 0.96 (95% CI 0.83–1.10)]. This represents 7 times the 
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reduction among girls in all-cause pneumonia rates compared to the boys. 
Among children with comorbidity, there was a 32% decline [RR 0.68 (95% CI 
0.56–0.82)] which was 3 times the decline in children without comorbidity [11%, 
RR 0.89 (95% CI 0.79–0.99)]. Those who were younger than 24 months of age 
experienced a 25% decline [RR 0.75 (95% CI 0.62–0.89)] in all-cause 
pneumonia, whereas older children experienced a 10% reduction [RR 0.90 (95% 
CI 0.80–1.02)] in the post-PCV13-era, which was statistically insignificant.  
 The evaluation of biologic interaction by interaction contrast calculations 
(Table 1.9) revealed that following implementation of PCV13, the rate of all-
cause pneumonia was less among girls compared to what would be expected 
based on the independent effects of PCV13-era and gender on all-cause 
pneumonia rates.  
2.4.3 Regression Analyses 
 
 Our time-series model constructed using the methodology outlined in the 
methods revealed that after controlling for seasonality and secular trends, at the 
end of 2013, rates of all-cause pneumonia in urban Boston children younger than 
8 years of age decreased by 135.2 (95% CI -27.4 to 297.8) per 10,000 (Table 
2.10 and Figure 2.5).  Among children younger than 2 years of age there was 
176.4 (95% CI 26.7 to 326.1) per 10,000 decline which amounted to a 35.3% 
(95% CI 5.4–65.3) reduction (Figure 1.6) and the difference between expected 
and observed pneumonia cases (“averted cases”) increased over years in the 
post-PCV13-era (Figure 2.7). Those children who were older than 2 years of age 
  23 
experienced a 132.9 (95% CI -14.4 to 280.1) per 10,000 decline which 
represented a 25.9% (95% CI -2.9 to 54.5) reduction (Figure 2.8). The declines 
among children with comorbidity were 38.8% (95% CI 11.1 to 65.4) and 28.7% 
(95% CI 2.9 to 54.5) for those younger than 2 years of age and those older, 
respectively (Figure 2.9). 
2.4.4. Bias Analyses 
 
 The results of the validation study using ICD-9 codes to define comorbidity 
using manual chart review as our gold standard to define presence of 
comorbidity are reported in Table 2.11. In this study, the sensitivity and specificity 
of ICD-9 codes to define comorbidity were 0.83 and 0.70, respectively.  
 Finally, we conducted a bias analysis to evaluate whether misclassification 
of comorbidity would affect the observed associations between PCV13-era and 
all-cause pneumonia rates, assuming a valid bias model and accuracy of 
assigned values to the bias parameters. In our bias analysis we used the 
sensitivity and specificity values calculated using the manual chart review in 
children with pneumonia and without pneumonia.  The corrected risk ratio for the 
association between PCV13-era and all-cause pneumonia was calculated as 
0.82 indicating that the observed association in the current data (RR=0.84), was 
biased towards the null compared with the corrected estimates as a result of 
imperfect predictive value for ICD-9 coding in defining the comorbidities. Our 
observed results would be an underestimate of a stronger PCV13 and all-cause 
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pneumonia association in case of misclassification of our comorbidity in this 
study. 
2.5 DISCUSSION  
 
 This study aimed to evaluate the disease burden of pneumonia in the 
post-PCV13 era compared to the pre-PCV13 era in urban settings in the U.S. 
and to assess the magnitude of the increased risk of pneumonia in children with 
comorbid conditions compared with healthy children. Consistent with our 
hypotheses, after controlling for seasonality and secular trends, implementation 
of PCV13 was associated with a significant reduction in all-cause pneumonia in 
urban Boston children, more prominently in younger children and in those with 
underlying comorbidities. By the end of 2013, among children younger than 2 
years of age there were 176.4 (95% CI 26.7 to 326.1) per 100,000 fewer cases of 
pneumonia which amounted to a 35.3% (95% CI 5.4–65.3) reduction and 
provides an estimate of the vaccine preventable burden of all-cause pneumonia 
in young children.  
 In randomized clinical trials, pneumococcal conjugate vaccines were 
shown to prevent pneumonia.28,29 However vaccine efficacy varies depending on 
the case definitions, vaccine formulations and study populations, and direct 
comparisons are difficult.  In addition, the effect of an immunization program can 
be different in an open population due to indirect protection which will impact 
both vaccinated and unvaccinated children. Our results are similar to those 
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reported from other post-licensure surveillance studies in different settings. 
Investigators from Scotland reported a 30% decline in pneumonia 
hospitalizations in children aged below 2 years following the introduction of 
PCV13.30 Moore et al. reported that the average annual number of culture-proven 
pneumococcal pneumonia cases in patients <18 years decreased by 53% after 
the introduction of PCV13 among the Active Bacterial Core surveillance sites. 
This estimate will be an overestimated reflection of the decline in all-cause 
pneumonia as S pneumoniae is the most common cause of bacterial pneumonia 
in almost all age groups. 31 Gaviria-Agudela et al. showed that cases of 
pneumonia decreased from 31.7% of IPD cases in the PCV7 era to 17% of cases 
in the PCV13 era through June of 2014 in Dallas, USA. 5 Substantial reductions 
in pneumococcal pneumonia among pediatrics patients were also reported in 
studies from Israel and Uruguay. 32,33 
 We also observed that the difference between expected and observed 
pneumonia cases (“averted cases”) increased over years in the post-PCV13-era. 
We consider this phenomenon as an indicator of indirect protection from PCV13 
via prevention of transmission of bacteria to unvaccinated individuals as a result 
of decline in PCV13 serotype colonization in immunized children. Our study was 
carried out in Massachusetts where traditionally there is a high vaccine coverage. 
The protective effectiveness of PCV13 against colonization was reported as 74% 
on average by Loughlin et al. in the same population and supports our 
conclusion.34 .  
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 Another interesting finding in our study is the impact of PCV13 on the all-
cause pneumonia rates among children with underlying comorbidities. Children 
with certain underlying conditions are reported to be at higher risk for IPD 
including pneumonia, and IPD cases in the PCV13 era are being more commonly 
noticed in patients with comorbidities. Olarte et al. showed that children with 
comorbidities are also more likely to experience a complicated disease course.35 
We observed a 38.8% reduction in all-cause pneumonia rates among children 
with comorbidity for those younger than 2 years of age, whereas there was a 
28.7% decline among older children with comorbidity who might be unvaccinated 
given their age, or might mount a less immunogenic response to vaccines given 
their underlying disease.36 This trend emphasizes the importance and the benefit 
of extended vaccine coverage particularly for those individuals who may not be in 
the target age group for the immunization program but yet are at high risk for 
more frequent and severe disease.  
 We also observed that gender was an effect modifier in the association 
between implementation of PCV13 and all-cause pneumonia. The decline in 
pneumonia rates was almost 7-fold higher among girls compared to boys, and 
the evaluation of biologic interaction showed that the rate of pneumonia among 
girls following PCV13 was less than what would be expected based on being 
female in the post-PCV13 era. Although there are well described gender 
differences in life expectancies, susceptibility and mortality with respect to 
pneumococcal disease, and even in response to vaccines as a result of the 
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impact of sex hormones on immunological cascades, the exact mechanism of the 
observed finding is unclear to us and will need to be evaluated with further 
studies.37  
 The current study has some limitations that are worth noting. First, 
identification of pneumonia was based on ICD-9 codes, and could be subject to 
misclassification. Diagnosis of pneumonia in general is based on clinical 
symptoms and clinical judgment, and therefore misdiagnosis and 
misclassification of pneumonia is always a possibility. In addition, the etiology of 
pneumonia, i.e. bacterial versus viral, is almost never identified in clinical 
settings. We do not expect this misclassification to be differential with respect to 
exposure, since to our knowledge there was no change in clinical practices such 
as new diagnostic testing, etc. to diagnose pneumonia in our study settings 
before and after implementation of PCV13. Thus, if it exists, this misclassification 
would bias our estimates towards the null and the reported decline in pneumonia 
rates would be an underestimate of the actual trend. Second, our study is a 
hospital based retrospective cohort study and children whose records were 
captured in the study may not reflect the whole population.  Third, if children with 
pneumonia received their diagnosis and care in another health care setting, we 
would not identify their outcome.  We tried to minimize this loss to follow up by 
selecting our participants based on attending at least one well child visit at one of 
the hospitals in the network which would be surrogate for using that network for 
healthcare. Fourth, secular trends such as changes in coding practices or 
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seasonal respiratory viral activity could potentially explain the differences in the 
pneumonia rates in different time points. Our models accounted for potential 
secular trends, seasonality and influenza activity in Massachusetts via time 
series analysis. We used urinary tract infections as control outcome, and 
observed no major changes in rates of urinary tract infection during the study 
period, which is reassuring. We believe that including a negative control outcome 
— urinary tract infections — and demonstrating that there were no unrelated 
trends for coding practices, etc. during the study period strengthens our findings 
that implementation of PCV13 was associated with these reductions in all-cause 
pneumonia rates. 
 Fifth, our study overlays trends in rates of all-cause pneumonia with the 
timing of PCV13 implementation without evaluating the vaccination status of 
each individual. We are limited in our ability to attribute this change to PCV13 
completely.   
 Sixth, comorbidities were coded dichotomously. Residual confounding by 
comorbidity severity may be present for those who had an underlying disease in 
this analysis. Furthermore, it is possible that children with underlying 
comorbidities are seeking medical care more frequently than otherwise healthy 
children, and the clinician has a lower threshold for diagnosing pneumonia given 
underlying disease. Additionally, further ascertainment of comorbidity status 
depends on ICD-9 use by the providers and is prone to misclassification. We 
  29 
conducted an in-depth chart-review of a sub-set population and performed 
sensitivity analysis to provide more accurate diagnosis of comorbidities as 
summarized above.  
 Finally, Streptococcus pneumoniae is widely recognized as the primary 
bacterial pathogen for community-acquired pneumonia in children. However, 
identifying the cause of pneumonia in individual cases is difficult and the other 
bacterial/viral pathogens cannot be ruled out with the design used in this study. 
In addition, without definitive bacteriologic data, the real incidence of 
pneumococcal pneumonia and serotypes responsible cannot be identified. This 
limits our ability to draw further conclusion about the impact of PCV13 
vaccination on pneumonia. 
 Despite these limitations, the current study is an important contribution to 
the current knowledge of the effectiveness of PCV13 against childhood 
pneumonia which remains the second leading cause of under-5 deaths 
worldwide. Our results reflect the population level impact of the PCV13 vaccine, 
particularly in urban settings which are traditionally reported to have a higher 
disease burden. Clinicians and public health professionals should be aware of 
the importance of improving vaccine coverage, which is one of the most effective 
tools to decrease preventable childhood mortality and to improve overall well-
being of children. 
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Table 2.3. Number of children per year (each child was counted once per year, 
but could be counted again for other years)* 
 
 
*N of children, can be counted multiple times in different years 
Cumulative Cumulative
Frequency Percent
2007 11101 15.24 11101 15.24
2008 11309 15.53 22410 30.77
2009 11480 15.76 33890 46.53
2011 12728 17.48 46618 64.01
2012 13046 17.91 59664 81.93
2013 13163 18.07 72827 100
Study year Frequency Percent
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Table 2.5. Baseline characteristics of study participants by study period 
 
Age (in months)
Mean
Sd
Race (n,%)*
White 2092 13.8 2085 13.0
Black 9370 61.9 9894 61.7
Hispanic 2297 15.2 2569 16.0
Asian 1372 9.1 1496 9.3
Private health insurance (n,%)
No 13907 75.9 16411 79.1
Yes 4414 24.1 4339 20.9
Primary Language (n,%)
English 13134 71.7 14309 69.0
Other 5187 28.3 6441 31.0
Comorbidity (n,%)
No 13189 72.0 15368 74.1
Yes 5132 28.0 5382 25.9
Immune-status (n,%)
Presumed immune 16504 90.1 19020 91.7
Presumed nonimmune 1817 9.9 1730 8.3
*Recorded for > 10% of the participants
2007-2009 2011-2013
40.2 42.2
31.7 31.6
2007-2009 2011-2013
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Table 2.6. Distribution of selected comorbidities by study periods 
 
 
Table 2.7. All-cause pneumonia rates among urban Boston children younger 
than 8 years of age before and after implementation of PCV13  
n % n %
Asthma
Yes 2006 10.9 2206 10.6
No 16315 89.1 18544 89.4
Chronic lung disease
Yes 108 0.6 93 0.4
No 18213 99.4 20657 99.6
Hemoglobinopathy
Yes 177 1.0 271 1.3
No 18144 99.0 20479 98.7
Congenital heart disease
Yes 45 0.2 57 0.3
No 18276 99.8 20693 99.7
HIV
Yes 9 0.0 12 0.1
No 18312 100.0 20738 99.9
2007-2009 2011-2013
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Table 2.9. Interdependence between PCV13 era and gender in predicting all-
cause pneumonia rates among children 
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Figure 2.2. Flow chart for selection of study participants 
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3  IMPACT OF BACILLE CALMETTE GUÉRIN VACCINATION ON 
TUBERCULIN SKIN TEST RESULTS AMONG CHILDREN 
 
3.1  ABSTRACT 
 
 Tuberculosis is a major global public health problem with particulary high 
disease burden in children worlwide. Bacille-Calmette-Guerin (BCG) vaccination 
continues to be the only vaccine available for prevention of TB and is used 
around the world. Tuberculin skin testing (TST) is an important tool for LTBI 
screening, particularly in resource limited settings, but is subject to false positive 
results secondary to prior BCG vaccination. Using the data collected via 
Tuberculosis Epidemiologic Studies Consortium (TBESC) study between 
September 2012 and September 2014, we examined the association between 
BCG vaccination and TST positivity. Logistic regression models were used to 
calculate adjusted prevalence ratios (PR and 95% confidence intervals. We 
identified 1992 children under <18 years of age who were tested with both TST 
and IGRAs. Prior BCG vaccination was reported in 1522 (76.4%) children, and 
602 (43.3%) children were found to be TST positive. Prior BCG vaccination had 
no impact on the TST results once adjusted for history of household contacts 
(adjusted PR 1.0, 95% CI 0.4–1.5). The results of this study add further evidence 
that BCG vaccination has little impact on TST in children, particularly in older age 
groups. 
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3.2  INTRODUCTION 
 
 Tuberculosis remains a major global health problem with an estimated 9 
million new cases and 1.5 million deaths reported worldwide in 2013.1 
Mycobacterium tuberculosis (Mtb), the bacillus causing tuberculosis2, is an 
airborne pathogen that is transmitted, almost exclusively, from person to person 
via shared air where the rate of transmission is governed by several factors, 
including the closeness of contact and duration of exposure.3–6 An estimated 2 
billion persons globally are infected with MTB-latent tuberculosis infection 
(LTBI).1 Most people exposed to Mtb show no evidence of clinical disease and 
remain asymptomatic, however the majority of people with TB disease fall ill 
through reactivation of LTBI acquired in the past.7 
 Children, especially those younger than 5 years, are at increased risk of 
exposure to infection, have increased risk of progressing from infection to 
disease and, if they develop disease, are at high risk of death.8,9  While only 5-
10% of adults with Mtb infection develop TB disease, up to 40% of Mtb-infected 
children <12 months of age progress to TB disease.4 The World Health 
Organization (WHO) 2016 Global Tuberculosis Report estimated that, in 2015, 1 
million children younger than 15 years got tuberculosis, and 210,000 died as a 
result of the disease.8  
 In countries where tuberculosis is endemic, the principal tool to prevent 
severe forms of the disease is Bacille-Calmette-Guerin (BCG) vaccination. BCG 
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was first introduced in 1921 and continues to be the only vaccine available for 
prevention of TB.10 It provides approximately 60% protection against pulmonary 
tuberculosis and greater protection for disseminated and meningeal disease.11,12 
However, BCG vaccination does not prevent acquisition of TB infection, and 
vaccinees can still develop LTBI.13,14  
Reactivation of LTBI accounts for the majority of active tuberculosis cases 
in the US.15 Therefore, a critical component of domestic tuberculosis prevention 
and control is the identification and treatment of persons with LTBI who are at the 
highest risk of progression to active TB disease. Because persons with LTBI are 
at greatest risk of progressing to active tuberculosis in the first 2 years after 
infection, timely and accurate identification and treatment of individuals with LTBI 
is necessary to intensify tuberculosis control.  
 There is no way to directly detect the presence of dormant Mtb bacillus in 
an individual, and diagnosis of LTBI is further hampered by the lack of a practical 
gold standard test. Currently, two screening modalities are approved and widely 
accepted for use in diagnosing LTBI: interferon-gamma release assays (IGRAs) 
and TST.5,16 Two FDA-approved IGRAs are available in the United States are the 
QuantiFERON-TB Gold In-Tube (QFT) and the T-SPOT.TB (T-Spot). The 
specific antigens used in IGRAs are produced by ESAT-6 and CFP-10 gene 
families not found in the BCG vaccine or in most environmental mycobacteria2,16–
18 38–41 making IGRAs highly specific for the diagnosis of active and latent TB.  
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 The TST is based on the development of delayed hypersensitivity to 
antigenic components of tuberculin in individuals infected with Mtb. Screening 
with TST is an important tool for the evaluation of contacts and suspected cases 
of TB particularly in resource limited settings where TB is endemic and has a big 
disease burden. However, since BCG vaccine is prepared using strains of 
Mycobacterium bovis that are closely related to Mtb, TST is reputed to be falsely 
positive due to previous BCG vaccination. In countries where BCG is part of the 
routine immunization schedule, assessing the effect of BCG vaccination on TST 
and appropriate interpretation of the results are crucial components of TB control 
programs. In addition, in countries such as the US, where BCG is not used but 
where there is a large population of foreign born individuals vaccinated with BCG 
at birth or, less commonly, at school, accurate interpretation of TST in the context 
of BCG vaccination history may have significant impact on efficacy of screening 
programs using TST.  
 Currently, there are conflicting reports on the effect of BCG vaccination on 
TST size. The proportion of children with prior BCG vaccination who have a 
positive TST result has been reported in a range of 0% to 90% depending on age 
at vaccination, interval between vaccination and testing, the BCG strain of BCG 
used, and geographical location.11,13 Mudido et al.20 found that BCG vaccination 
at birth had no significant effect on the TST results in Ugandan children, similar 
to Menzies21 et al. who reported that in patients studied in Quebec, BCG 
vaccination was unlikely to cause a positive TST result. Contrary to these 
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reports, many other studies19 including a study by Ormerod et al.22 found high 
levels of TST positivity four years following BCG vaccination among children who 
were vaccinated during infancy.  
 The uncertainty of the effect of BCG vaccination on TST results and 
interpretation affects early diagnosis and treatment of LTBI cases. Therefore, we 
aimed to evaluate the impact of BCG vaccination on TST among children <18 
years enrolled in the Tuberculosis Epidemiologic Studies Consortium (TBESC) 
study between September 2012 and September 2014, to provide further insight 
to formulate the most effective strategies for LTBI screening among children. 
3.3  METHODS 
3.3.1. Study Population  
The study population included foreign-born children <18 years of age who 
were enrolled in the TBESC Study 1 during the first two years of the study 
(between September 2012 and September 2014). TBESC Study 1 is a 
prospective cohort study which has 10 study sites across the United States 
administered by the Division of Tuberculosis Elimination Surveillance, 
Epidemiology, and Outbreak Investigations at the Centers for Disease Control 
and Prevention 10, and will continue to enroll until September 2019 (Figure 3.1). 
The study sites are:  
• California Department of Public Health, California 
• Denver Health and Hospital Authority, Colorado 
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• Duke University, North Carolina and Tennessee 
• Emory University, Georgia 
• Hawaii Department of Health, Hawaii 
• Public Health-Seattle and King County, Washington 
• Maricopa County Department of Public Health, Arizona 
• Maryland Department of Health and Mental Hygiene, Maryland 
• University of Florida, Florida 
• University of North Texas Health Science Center, Texas 
  Individuals who are at high risk for LTBI or at high risk for progression to 
TB disease were enrolled in TBESC Study 1. Persons were considered to be at 
high risk if they were:  
• A close contact of a person with pulmonary TB who is part of a 
current contact investigation and the index/source case meets the 
following criteria:  
o culture-positive, OR  
o culture-negative and smear positive and nucleic acid 
amplification test (NAAT) positive.  
A close contact is defined as spending 15 or more hours over a 
week’s period in a shared airspace with a person with active 
pulmonary TB while that person was presumed to be infectious.   
• A foreign-born person from a high-risk country, as listed in Appendix 
A. 
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• A foreign-born person from a medium risk country who moved to the 
United States within the past 5 years, as listed in Appendix A. 
• A person who has spent at least 30 days in total in a high-risk country 
within the last 5 years, as listed in Appendix A. 
• A person belonging to a population with a prevalence of LTBI ≥ 25% 
as demonstrated by local surveys.  These populations will vary by 
site; examples include Mexican immigrants in San Diego, California 
or homeless drug users in Baltimore, Maryland. 
• An HIV-seropositive person. 
  Persons who had active TB, a previous anaphylactic reaction to tuberculin 
used in TST, were anticipating or scheduled to permanently leave the United 
States (e.g., tourists, visiting scholars, and exchange students) in less than 2 
years from the time of proposed study enrollment, and foster children were 
excluded from the study.   
3.3.2. Data Collection  
  Standardized data collection forms were administered by trained study 
personnel to collect information on demographics, risk factors, potential 
tuberculosis exposure, and self-reported medical history from all study 
participants and their parents.  If a participant did not know the answers to 
questions, study staff tried obtain this information from available medical records. 
Cohort data includes information about demographics, vaccination history, 
underlying comorbid conditions, risk factors including but not limited to country of 
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origin, exposure to individuals with active TB, chest X-ray results, etc., and 
screening results. For each participant, three different LTBI screening tests (TST, 
QFT, and T-Spot) were administered on the day they enrolled in the study. The 
TST was placed and read by trained study staff in a standardized manner which 
included using a tuberculin syringe, 5 tuberculin unit of purified protein derivative 
(PPD) that was injected intradermally into the volar surface of the forearm. Study 
staff also obtained blood samples for the IGRAs and results were interpreted by 
CDC and manufacturer recommendations.15  
3.3.3. Definition of Variables 
Exposure 
  Receipt of any BCG vaccination was ascertained using questionnaires 
that were administered at the time of enrollment visits. For individuals with 
available prior vaccine records information was transferred to study questionnaire 
but for others with no immunization records verbal report/self-reported medical 
history was used to assign BCG vaccination.  
Outcome 
  TST results were ascertained using the data collection forms filled by the 
study staff who evaluated the test result within 48–72 hours after its 
implementation. Positive results were defined using a cutoff of >=10 mm 
induration size (Table 2.1). 
Covariates 
 Covariates obtained from the TBESC dataset include age, gender, 
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ethnicity/race, country of origin, time since BCG vaccination, self-reported close-
contact to patients with TB (yes/no), underlying conditions that are considered to 
confer increased risk for developing active TB disease (yes/no) per CDC and 
WHO guidelines.1,5,16,42–44 These conditions included but were not limited to HIV 
status, weight, previous stay at a refugee camp, low socio-economic status 
measure by monthly income and education levels, current or past smoking, 
history of being homeless, shelter stay, injection drug use, history of 
incarceration, organ transplant, cancer, diabetes, end-stage renal disease or liver 
disease. Age at vaccination was defined using the vaccination record if available 
or was based on the country of birth and the immunization policy/schedule in the 
country reported by the WHO (Figure 3.2).16 Body mass index (BMI) was 
calculated using the weight and height recorded at the time of enrollment by 
using the following formula: BMI=weight/height2. BMI was categorized as: <18.5 
(underweight), 18.5–24.9 (normal weight), 25.0–29.9 (overweight) and ≥30.0 
(obese). IGRA was defined as positive if either of the T-Spot or QFT testing was 
positive, and defined as negative if both of the T-Spot and QFT testing were 
negative.   
3.2.4. Statistical Analysis 
 First, descriptive analyses were conducted to assess the proportion of 
cases (children with positive TST results) and non-cases (children with negative 
TST results) within strata of important demographic variables (e.g. age, gender), 
BCG-vaccination, and other important predictors of TST positivity (country of 
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origin, age at vaccination, exposure to individuals with active TB, household 
contact with individuals with TB, presence of comorbidities, etc.). After calculating 
the crude prevalence ratio of the association between BCG vaccination and a 
positive TST result, some potential confounders and modifiers were assessed via 
stratification. Adjusted prevalence ratios were calculated for each potential 
confounder using either standardized mortality ratios when ratios were 
heterogeneous across strata or Mantel-Haenszel pooled ratios when effects were 
homogeneous across strata. 95% confidence intervals were also calculated. For 
any table in which a cell frequency was 5 or less, we calculated Fisher's exact 
ratios and exact confidence intervals. Variables that had an adjusted prevalence 
ratio demonstrating a change greater than 10% in crude prevalence ratios were 
utilized in all of the later models in the study. 
  Finally, multivariate regression was used to estimate prevalence ratios of 
TST positivity among children who received BCG vaccination compared to those 
who did not. To create a final model, the impact that each potential confounder 
had on the association between prior BCG vaccination and TST positivity was 
assessed by adding the potential confounder to the regression model one at a 
time. Then relative risk due to confounding (RRc) was calculated by comparing 
the crude prevalence ratio to the one obtained from the model including only the 
potential confounder and the primary exposure. If RRc was found outside of the 
range of 0.9 and 1.1 or the potential confounder was thought to be clinically 
significant depending on the published literature, then the covariate was retained 
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in the model as a confounder. This method was repeated with the remaining 
potential confounders in order of strength.  
 All analyses were conducted using SAS version 9.1.3. 45 
3.4  RESULTS 
3.4.1 Descriptive Analyses 
 A total of 2164 foreign-born children under 18 years of age with valid 
results for TST, QFT and T-Spot were identified in TBESC participants and 1992 
(92.1%) had complete information on BCG vaccination and were included in the 
analysis (Figure 3.3). The sample characteristics of the current study are 
displayed in Table 3.2. The mean age for all children in the study was 9.7 
(standard deviation 4.7) years, and 1094 (49.7%) were female (Figure 3.4). A 
majority of the study participants defined their race/ethnicity as Asian (727/1992, 
36.5%), African/American (354/1992, 17.8%) and Hispanic/Latino (99/1992, 
5.0%). Body mass index calculated using recorded weight and height at 
enrollment was less than 18.5 for 1253/1827 (68.6%) children classifying them as 
“underweight”. Approximately 1/5th (21.7 %) of the children in the study had no 
formal school training, whereas 40.3% reported formal school education less 
than 8th grade level. Table 2.3 depicts the country of birth of children who 
participated in the study; among these 822 (41.3%), 769 (38.6%) and 401 
(20.1%) were from low, medium and high TB-incidence countries, respectively. 
There were 2 cases (0.1%) who self-reported HIV; Table 2.2 shows the 
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distribution of all comorbidities assessed in the study. Two-hundred-forty (12.0%) 
children had a positive IGRA test result (Figure 3.5). Prior BCG vaccination was 
reported in 1522 (76.4%) children. 
 The TST induration size ranged between 0 to 60 mm, with a median of 0 
mm in all children (Table 3.4). Six-hundred-two (30.2%) children had ≥10 mm 
induration at the end of 72 hours. TST positivity was observed in 38.3%, 26.0%, 
21.7%, 37.8 and 33.8% of children <2 years, 2–4 years, 5–9 years, 10–14 years 
and 15–<18 years of age, respectively. In our study, 35.1% of Asian, 29.7% of 
African/American, 77.8% of Hispanic/Latino, 14.0% of White and 8.5% of 
Hawaiian/Islander children were found to have positive TST (Table 3.2). 
Approximately 1/4th (26.2%) of underweight children had positive TST results, 
whereas 36.2%, 28.1% and 34.0% of normal, overweight and obese children had 
positive TST results, respectively.  
 TST was positive in 39.7% of children who had close contact with a TB 
case and 40.9% of children with previous exposure to household TB cases. 
Among those who had exposure to a household TB case within last 2 years, TST 
positivity was 34.7% whereas it was 40.9% among children who had exposure to 
a household TB case more than 2 years ago.  
 Among children with positive TST results, 507/602 (84.2%) had prior BCG 
vaccination, whereas only 1015/1390 (73.0%) children with negative TST results 
had received a prior BCG (Table 3.5). 
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3.4.2 Stratified Analyses 
 
 The results of the stratified analyses examining the association between 
prior BCG vaccination and TST positivity are displayed in Table 3.6. The crude 
prevalence ratio for this association was 1.7 (95% confidence interval 1.4–2.0). 
Household TB contact, time since this household contact, and race were 
confounders for the association between BCG vaccination and TST positivity in 
our study population. After adjusting for household TB exposure, the prevalence 
ratio was reduced to 1.0 (95% confidence interval 0.66–1.7). Similarly, once we 
adjusted for time since household TB exposure the prevalence ratio was reduced 
to 1.0 (95% confidence interval 0.4–1.5). The adjusted prevalence ratio for race 
ratio reduced to 1.5 (95% confidence interval 1.2–1.9).   
3.4.3 Regression Analyses 
 Multivariable regression analyses were conducted to examine the 
association between prior BCG vaccination and TST positivity adjusting for 
household TB exposure, time of household TB exposure, and race, which were 
confounders identified using the methods outlined in Methods section (Table 
3.7). The final model retained BCG vaccination as the primary exposure and 
close TB contact as the only confounder. The adjusted prevalence ratio for the 
association between prior BCG vaccination and TST positivity was 1.0 (95% 
confidence interval 0.6–1.7). 
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3.5  DISCUSSION 
 
 Timely and accurate diagnosis of LTBI is an important component of any 
successful TB elimination program, and skin testing is the most widely used 
approach for LTBI screening. The uncertainty of the effect of BCG vaccination on 
TST results and interpretation affects early diagnosis and treatment. This study 
aimed to evaluate the impact of BCG vaccination on TST results among children 
<18 years of age who were enrolled in the TBESC study between September 
2012 and September 2014, and to provide further insight to formulate the most 
effective strategies for LTBI screening among children.  
 We demonstrated that prior BCG vaccination had no impact on the TST 
results once adjusted for history of household contacts (adjusted prevalence ratio 
1.0, 95% CI 0.4–1.5). This finding is consistent with other studies from different 
countries with high TB endemicity. Modido et al. reported that BCG vaccination at 
birth had no significant effect on the interpretation of the TST reactivity in 
Ugandan children, and concluded that TST remains a valuable tool for evaluation 
of suspected cases of TB in BCG-vaccinated children.20 Other studies showed a 
high rate of TST negativity among children, particularly in younger age groups, 
even in countries which have BCG vaccination at birth in routine immunization 
schedule. 21,24,25 A recent study from Gambia found that TST results were not 
affected by BCG vaccination and the performance of the TST and IGRAs is 
similar for the diagnosis of LTBI.26  
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 On the other hand, some studies concluded that particularly in low TB 
endemicity settings, positive TST results can be attributed to prior BCG 
vaccination. In a meta-analysis Farhat et al. reported an approximate 42% false 
positivity for TST testing among BCG-vaccinees.27 Similarly, Wang et al. 
demonstrated that patients who received BCG vaccination were 2 times more 
likely to have a positive TST.19 These conflicting findings can potentially be 
explained by different immunological and epidemiological dynamics in host 
response to BCG vaccine and TB infection. The age at which BCG vaccine is 
given is an important determinant of the immune response to BCG. Infants mount 
less immune response to BCG compared to children who receive the vaccine at 
older ages.28,29 In addition, time since vaccination is important. BCG vaccination 
was found to have no impact on TST results when TST was performed at least 
15 years after BCG vaccination.30 In a meta-analysis involving 24 studies and 
240,203 infants vaccinated with BCG at birth, only 1% were TST-positive when 
tested >=10 years after BCG.46 In a recent study from Spain, the differences in 
false positive rates in TST results found among BCG vaccinated and non-
vaccinated children disappeared after 3 years of life.31  
 Another interesting finding in our study is the impact of household contact 
to a TB case on the TST positivity. As has been reported previously, close 
household contact with a TB case is the strongest predictor of TST positivity in 
children.5,6 As the mycobacterial load in the sputum from a TB case increases, 
the infectivity also increases, and children who reside in the same household as 
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a smear-positive adult are at higher risk to get infected.6 In studies where 
participants are from countries with high TB prevalence rates, it is more likely that 
children would have been exposed to a household TB case, would have had 
BCG, and would have LTBI independent from whether they were vaccinated or 
not. In this situation, our results support that TST positivity should be a trigger to 
further evaluation to differentiate LTBI and TB disease to provide appropriate 
treatment.    
 Our study has several limitations. First, the study sample was restricted to 
children who emigrated from different countries, most of which had high TB 
prevalence. Further, many of the children in the study sample stayed in a refugee 
camp for some period of time. Given the transmission dynamics of TB infection, 
the findings from the current study cannot be directly applied to low TB-endemic 
settings. Second, BCG vaccination was defined based on self-report which may 
lead to misclassification. Third, TST measurement is subject to interpersonal 
variation and can contribute to measurement error.  Our study was nested within 
a larger prospective cohort study utilizing detailed standardized protocols and 
recurrent trainings for investigators, which was intended to minimize 
measurement variation. Fourth, the “time of vaccination” was defined using the 
country specific schedules reported by WHO and is subject to misclassification. 
We also relied on self-report for presence of household contact which can also 
cause further misclassification and residual confounding. Fifth, the cut-off point 
for positive TST in defining LTBI is arbitrary.  
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 Despite these limitations, the current study adds an important analysis to 
the literature by controlling for confounding by household exposure. Our results 
emphasize that interpretation of TST should be made in the individual clinical and 
risk context. Attributing a 'positive' TST response to past BCG vaccination may 
be encouraging a false sense of security among children with history of exposure 
to an infectious case of TB.  
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3.7. TABLES  
 
Table 3.1. Classification of tuberculin skin test induration sizes  
A recent contact of a person with TB disease
Patients with organ transplants
Persons who are immunosuppressed for other reasons (e.g., taking the 
equivalent of >15 mg/day of prednisone for 1 month or longer, taking TNF-
a antagonists)
HIV-infected persons
Persons with fibrotic changes on chest radiograph consistent with prior TB
Infants, children, and adolescents exposed to adults in high-risk categories
Children < 4 years of age
Injection drug users
Mycobacteriology laboratory personnel
Persons with clinical conditions that place them at high risk
Recent immigrants (< 5 years) from high-prevalence countries
Residents and employees of high-risk congregate settings
An induration of 10 or more mm 
is considered positive in
An induration of 5 or more mm 
is considered positive in
>An induration of 15 or more 
mm is considered positive in
Any person, including persons with no known risk factors or TB. However, 
targeted skin testing programs should only be conducted among high-risk 
groups.
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Table 3.2. Summary of population characteristics 
  
n %* n %** n %**
Age Groups
<2 years 94 4.7 36 38.3 58 61.7
2-4 years 335 16.8 87 26.0 248 74.0
5-9 years 636 31.9 138 21.7 498 78.3
10-14 years 699 35.1 264 37.8 435 62.2
15-<18  years 228 11.4 77 33.8 151 66.2
Gender
Female 990 49.7 287 29.0 703 71.0
Male 1002 50.3 315 31.4 687 68.6
Race
Asian 727 36.5 255 35.1 472 64.9
AfricanAmerican 354 17.8 105 29.7 249 70.3
Hispanic/Latino 99 5.0 77 77.8 22 22.2
White 93 4.7 13 14.0 80 86.0
Hawaiian/Islander 47 2.4 4 8.5 43 91.5
Other 560 28.1 114 20.4 446 79.6
Unknown 112 5.6 34 30.4 78 69.6
Weight
Underweight 1253 68.6 328 26.2 925 73.8
Normal 464 25.4 168 36.2 296 63.8
Overweight 63 3.4 24 38.1 39 61.9
Obese 47 2.6 16 34.0 31 66.0
Education Level
No schooling 433 21.7 111 25.6 322 74.4
<= 8th grade 803 40.3 217 27.0 586 73.0
Some high school 258 13.0 83 32.2 175 67.8
High school graduate or GED 245 12.3 89 36.3 156 63.7
Trade school or associate's degree 16 0.8 8 50.0 8 50.0
Some university/college 48 2.4 21 43.8 27 56.3
University/college graduate 151 7.6 61 40.4 90 59.6
Postgraduate schooling 19 1.0 8 42.1 11 57.9
Other 4 0.2 0 0.0 4 100.0
DK/Refused 15 0.8 4 26.7 11 73.3
*Column percentages, **row percentages, # when available 
TST <10 mm 
(n=1390)
All children   
(n=1992)
TST >=10 mm  
(n=602)
  76 
Table 3.2. Summary of population characteristics (continued)  
n %* n %** n %**
Monthly Income
<$100 595 29.9 135 22.7 460 77.3
$100-$500 208 10.4 58 27.9 150 72.1
$501-$1000 266 13.4 81 30.5 185 69.5
$1001-$2000 247 12.4 80 32.4 167 67.6
$2001-$3000 69 3.5 22 31.9 47 68.1
$3001-$4000 25 1.3 10 40.0 15 60.0
$4001-$5000 11 0.6 7 63.6 4 36.4
>$5000 15 0.8 6 40.0 9 60.0
DK/Refused 556 27.9 203 36.5 353 63.5
Birth Country TB Risk Groups
Low (<125/100,000) 822 41.3 228 27.7 594 72.3
Moderate (125-299/100,000) 769 38.6 260 33.8 509 66.2
High (>=300/100,000) 401 20.1 114 28.4 287 71.6
Close contact# 146 7.6 58 39.7 88 60.3
Household TB exposure# 88 62.0 36 40.9 52 59.1
Household TB exposure timing#
Within last 2 years 75 52.8 26 34.7 49 65.3
More than 2 years ago 67 47.2 30 44.8 37 55.2
HIV/AIDS 2 0.1 0 0.0 2 100.0
Hepatitis 4 0.2 2 50.0 2 50.0
Renal failure 0 0.0 0 0.0 0 0.0
Diabetes 4 0.2 2 50.0 2 50.0
Steroid use 2 5.4 0 0.0 2 100.0
Pregnant 1 0.3 0 0.0 1 100.0
Holding center 926 46.6 188 20.3 738 79.7
Correction facility 2 0.3 0 0.0 2 100.0
Drug facility 1 0.3 1 100.0 1 100.0
Longterm facility 14 7 6 42.9 8 57.1
Homeless 4 0.2 0 0.0 4 100.0
Smoked >100 ciggaretes in life 13 5.6 6 46.2 7 53.8
Current smoker 4 28.6 1 25.0 3 75.0
Alcohol use
Never 222 95.7 74 33.3 148 66.7
Once a month or less 5 2.2 4 80.0 1 20.0
2-3 times a month 2 0.9 0 0.0 2 100.0
Once per week 1 0.4 0 0.0 1 100.0
2-3 times a week 2 0.9 0 0.0 2 100.0
4 or more times a week 0 0.0 0 0.0 0 0.0
Recreational drug use 3 1.3 1 33.3 2 66.7
IGRA positivity 240 12.0 195 81.3 45 18.8
*Column percentages, **row percentages, # when available 
All children   
(n=1992)
TST >=10 mm  
(n=602)
TST <10 mm 
(n=1390)
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Table 3.3. Country of origin for children enrolled in the study 
 
  
Birth country N %
Nepal 322 16.2
Myanmar 217 10.9
Iraq 197 9.9
Thailand 193 9.7
Malaysia 143 7.2
Philiphines 139 7.0
Mexico 69 3.5
Kenya 63 3.2
Ethiopia 55 2.8
Rwanda 50 2.5
Somolia 49 2.5
Marshall islands 45 2.3
Congo (Brazzaville) 39 2.0
Haiti 36 1.8
Democratic Republic of the Congo 33 1.7
Afganistan 27 1.4
Djibouti 25 1.3
Uganda 20 1.0
South Africa 20 1.0
Egypt 18 0.9
Eritrea 15 0.8
Vietnam 14 0.7
Sudan 13 0.7
Guatemala 11 0.6
Slovenia 11 0.6
Iran 11 0.6
Bhutan 10 0.5
China 10 0.5
Other 137 6.9
Total 1992 100.0
*Those with >10 individiuals are listed
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Table 3.5. Crude association between BCG vaccination and TST positivity  
  
 
 
 
TST >=10 mm  TST <10 mm  Prevalence ratio
BCG vaccinated 507 1015
BCG unvaccinated 95 375
Total 602 1390
1.7 (1.4-2.0)
  80 
Table 3.6. Stratified analyses of the association between BCG vaccination and 
TST positivity with crude and adjusted prevalence ratios
TST >=10 mm  
(n=602)
TST <10 mm 
(n=1390)
Prevalence ratios 
(95% CI)
BCG vaccinated 507 1015 1.7 (1.4-2.0)
Age <2 years BCG vaccinated 29 45
BCG unvaccinated 7 13
2-<5 years BCG vaccinated 74 183
BCG unvaccinated 13 65
5-<10 years BCG vaccinated 119 375
BCG unvaccinated 19 123
10-<15 years BCG vaccinated 226 318
BCG unvaccinated 38 116
15-<18 years BCG vaccinated 59 93
BCG unvaccinated 18 58
Adjusted for age 1.7 (1.4-2.0)
Underweight BCG vaccinated 273 684
BCG unvaccinated 55 241
Normal BCG vaccinated 143 207
BCG unvaccinated 25 89
Overweight BCG vaccinated 23 27
BCG unvaccinated 1 12
Obese BCG vaccinated 13 20
BCG unvaccinated 3 11
Adjusted for BMI 1.7 (1.4-2.1)
Close contact + (#) BCG vaccinated 46 70
BCG unvaccinated 12 18
Close contact - (#) BCG vaccinated 452 913
BCG unvaccinated 78 342
Adjusted for close contact 1.7 (1.4-2.0)
House hold contact + (#) BCG vaccinated 29 43
BCG unvaccinated 7 9
House hold contact - (#) BCG vaccinated 16 24
BCG unvaccinated 5 9
Adjusted for HH (#) when available 1.0 (0.6-1.7)
*COB Country of birth 
**Adjusted estimate is a standardized mortality ratio due to heterogenicity across strata
(#) when available
1.1 (0.6-2.2)
1.7 (1.0-2.9)
1.8 (1.2-2.8)
1.6 (1.1-2.6)
1.7 (1.3-2.3)
0.9 (0.5-1.7)
1.1 (0.5-2.5)
1.8 (1.4-2.2)
1.5 (1.2-2.0)
1.9 (1.3-2.7)
5.9 (0.9-40.3)
1.8 (0.6-5.5)
1.0 (0.6-1.6)
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Table 3.6. Stratified analyses of the association between BCG vaccination and 
TST positivity with crude and adjusted prevalence ratios (continued)
TST >=10 mm  
(n=602)
TST <10 mm 
(n=1390)
Prevalence ratios 
(95% CI)
HH contact within 2 years (#) BCG vaccinated 18 40
BCG unvaccinated 8 9
HH contact longer than 2 years (#) BCG vaccinated 26 28
BCG unvaccinated 4 9
Adjusted for time of HH 1.0 (0.6-1.5)
Low TB incidence at COB* BCG vaccinated 190 441
BCG unvaccinated 38 153
Moderate TB incidence at COB* BCG vaccinated 223 392
BCG unvaccinated 37 117
High TB incidence at COB* BCG vaccinated 92 181
BCG unvaccinated 20 105
Adjusted for TB incidence at COB 1.6 (1.3-2.0)
Indian/Alaska Native BCG vaccinated 0 0
BCG unvaccinated 0 3
Asian BCG vaccinated 215 354
BCG unvaccinated 40 118
African american BCG vaccinated 79 161
BCG unvaccinated 26 88
White BCG vaccinated 11 59
BCG unvaccinated 2 21
Hawaiian/Islander BCG vaccinated 2 15
BCG unvaccinated 2 28
Hispanic/Latino BCG vaccinated 73 18
BCG unvaccinated 4 4
Adjusted for race 1.5 (1.2-1.9)
*COB Country of birth 
**Adjusted estimate is a standardized mortality ratio due to heterogenicity across strata
(#) when available
2.1 (1.4-3.3)
1.5 (1.1-2.0)
1.5 (1.1-2.1)
∞
1.5 (1.1-2.0)
1.4 (1.0-2.1)
1.6 (0.7-3.7)
1.8 (0.4-7.6)
1.8 (0.3-11.4)
1.6 (0.8-3.2)
0.7 (0.4-1.2)
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Table 3.7. Results of multivariate regression analysis   
  
 
 
 
 
Model parameters PR 95% confidence interval 
BCG vaccination 1.7 1.7-2.0
BCG vaccination and household TB exposure 1 0.6-1.7
BCG vaccination, household TB exposure and race 1 0.6-1.7
BCG vaccination, household TB exposure and time of 
household exposure 1 0.6-1.8
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3.8 FIGURES 
 
Figure 3.1 Study sites * 
 
*https://www.cdc.gov/tb/topic/research/tbesc/default.htm 
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Figure 3.3 Study flow diagram 
TBESC Tuberculosis Epidemiologic Studies Consortium, TST Tuberculin skin test,
QFT QuantiFERON-TB Gold, BCG bacille Calmette-Guerin
Enrolled in TBESC (n=12,134 )
<18 years of age and foreign-born (n=2,164) 
Missing BCG information (n=172)
Analyzed (n=1,992 )
Had valid results for TST, QFT, TSPOT (n=10,754)
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Figure 3.4 Age distribution of pediatric study participants  
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4 THE COST-EFFECTIVENESS OF SCREENING FOR LATENT 
TUBERCULOSIS INFECTION IN THE UNITED STATES 
 
4.1  ABSTRACT 
 
Tuberculosis (TB) remains a serious public health problem with long term-
health and economic consequences. Screening for latent tuberculosis infection 
(LTBI) to provide early diagnosis and treatment is a major cornerstone in an 
effective TB control and prevention program. Timely and accurate identification 
and treatment of LTBI particularly in high risk groups such as individuals from 
high risk countries can improve TB control programs. Currently, two screening 
modalities are approved and widely accepted for use in diagnosing LTBI: 
tuberculin skin testing (TST) and interferon-gamma release assays (IGRAs). We 
performed a cost-effectiveness analysis comparing different LTBI screening 
strategies in a population with a high proportion of foreign-born individuals who 
have different risk levels for developing TB using data from Tuberculosis 
Epidemiologic Studies Consortium (TBESC) Study-1, a 10-site collaboration of 
academic institutions and state and local TB control programs that is funded and 
administered by the Division of Tuberculosis Elimination at the Centers for 
Disease Control and Prevention (CDC). We used decision tree analysis and 
Markov models to compare TST only, IGRA only, TST followed by IGRA among 
those who were TST positive, and no screening strategies. Regardless of the 
assumptions and tests used, screening provided better health outcomes such as 
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less TB cases and less TB related mortality compared to no screening. The dual-
test strategy with TST followed by IGRA was the most cost-effective approach 
with an incremental cost-effectiveness ratio (ICER) $75,094 per QALY gained 
compared to no screening. For TST alone and IGRA alone compared to no 
screening, ICERs were $127,164 and $140,632 per QALY, respectively. 
Prioritizing certain groups for targeted LTBI screening such as foreign-born 
individuals, and using TST followed by IGRA to improve the efficiency of the 
screening program has the potential to maximize the impact of public health 
resources allocated to eradicate TB in the U.S.  
.  
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4.2  INTRODUCTION 
 
 Worldwide, tuberculosis (TB) claims more lives than any other infectious 
diseases with   significant long-term health and economic consequences.1 It is 
estimated that one third of the world’s population is infected with Mycobacterium 
tuberculosis (Mtb) and approximately 5–10% of those can later develop active TB 
disease. An estimated 11 million people living in the United States have latent 
tuberculosis infection (LTBI), and reactivation of LTBI accounts for 70% of active 
TB cases.2,3 Screening for LTBI to provide early diagnosis and treatment is a 
major cornerstone in an effective TB control and prevention program. In 
developed countries such as United States, foreign-born individuals compose the 
majority of the LTBI and new TB cases with highest incidence of TB occurring 
during the first year of their arrival.4  
 In the United States, screening for TB is mandatory for all immigrants 
seeking for permanent residency as part of their visa application process. 
However, TB screening is not required for persons who enter to the United 
States to attend school, engage in business, or participate in leisure activities 
even though some of these persons may come from countries with high TB rates. 
This serves as a reservoir of new TB cases that can cause secondary cases in 
countries where domestic TB incidence is low.5 Similar trends have been 
reported from many developed countries such as Norway, where TB incidence 
largely reflects the level of immigration from countries with high TB burden.6 
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Timely and accurate identification and treatment of LTBI particularly in high risk 
groups such as individuals from high risk countries can prevent the occurrence of 
TB disease and improve TB control.  
 Currently, two screening modalities are approved and widely accepted for 
use in diagnosing LTBI: TST and interferon-gamma release assays (IGRAs).3,7 
Two FDA-approved IGRAs are available in the United States: the QuantiFERON-
TB Gold In-Tube (QFT) and the T-SPOT.TB (T-Spot). The specific antigens used 
in IGRAs are produced by ESAT-6 and CFP-10 gene families not found in the 
BCG vaccine or in most environmental mycobacteria making IGRAs more 
specific for the diagnosis of active and latent TB.3,8–10 IGRAs also have several 
operational advantages over TST as a single specimen of peripheral blood is 
adequate and there is no need for subsequent visit or trained personnel on site 
for interpretation. The caveats of screening with using IGRAs include their 
relatively high cost, need for laboratory infrastructure as well as lack of 
consensus on how to define and interpret conversions, reversions and 
nonspecific variations that occur with IGRA serial testing.   
 Thus far, the outstanding question of which test is most appropriate for 
use in LTBI diagnosis remains to be determined and clinicians use different 
approaches in practice. Some guidelines suggest using TST or IGRA, but not 
both, as a screening tool for LTBI in close contact of persons with infectious TB.11 
This differs from other guidelines from professional societies in UK or Canada, 
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where two-step approach with TST followed by IGRA to confirm positive results 
is recommended. For low- and middle-income countries with high disease 
burden, given cost, technical complexity and comparable performances, WHO 
does not advise using IGRAs.10 The fact that these guidelines do not yet provide 
a consensus on the optimal screening method for LTBI indicates the need for 
further research to develop most effective screening strategies and 
recommendations are likely to evolve as more data are accumulated. 
 When implementing public health programs for preventing infectious 
diseases the safest, the most efficacious, and effective intervention with the 
lowest possible cost per case of illness prevented should be the standard. Given 
the fact that we have ever-increasing health demands in the setting of finite 
resources, systematic economic evaluation of health care services is crucial. In 
terms of TB elimination efforts, the first cost-effectiveness analysis of LTBI 
treatment was published by Snider et al. in 1986 which examined different 
durations of INH therapy for LTBI and showed 6 months therapy was cost-
effective.12 In many subsequent studies, LTBI screening and treatment using INH 
have been reported to be cost-effective and even cost-saving in some 
populations.13–15 However, published studies on cost effectiveness of LTBI 
screening focused on using TST only, or IGRA only compared to no screening, 
and were carried out in different populations which may have different LTBI 
prevalence. A limited number of studies compared using TST to IGRA in LTBI 
screening, but none of the studies included the results of all tests done in the 
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same individual and have reached to different conclusions. Erkens et al.16 
concluded that TST used in combination with IGRA was cost-effective compared 
to using IGRA alone, whereas Campbell et al.17 found IGRA alone to be 
moderately cost-effective in their systemic review. Kowada et al.18 reported TST 
and IGRA combined was most cost effective among immigrants from high-risk 
countries, but IGRA alone was dominating other strategies in other populations. 
Further, there are many groups with more than one risk factor — i.e. foreign-born 
diabetics etc. In these groups, the answer is not clear. On the one hand, they 
have high prevalence and increased risk of active TB. On the other hand, 
competing risks from co-morbidities may limit the benefits of screening.  
 The aim of this study was to assess the cost-effectiveness of available 
LTBI screening tools in a population with high proportion of foreign-born 
individuals who have different risk levels for developing TB using data from 
TBESC study 1 in order to provide further insight in formulating the most effective 
screening strategies for LTBI. 
4.3  METHODS 
 
4.3.1 Study Population 
  The study population included individuals who were enrolled in the TBESC 
during the first two years of the study between September 2012 and September 
2014. TBESC is a prospective cohort study which is described in detail in Study 
2. In this study, each individual was tested with using three different tools for 
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LTBI: 1) TST 2) T-Spot and 3) QFT during their enrollment visit. Individuals who 
had results for all of three tests were included in the analyses. Study flow is 
summarized in Figure 4.1. 
4.3.2 Data Collection  
 Standardized data collection forms were administered by trained study 
personnel to collect information on demographics, risk factors, potential 
tuberculosis exposure, and self-reported medical history from all study 
participants as described in Study 2.  
4.3.3 Cost effectiveness analysis 
 Decision tree (Figure 4.2) and Markov models (Figure 4.3) were 
developed to simulate and compare the clinical progression and outcomes for the 
following LTBI screening strategies: 1) No screening; 2) Using TST as a stand-
alone tool with >10mm as induration cutoff size; 3) Using IGRA alone; 4) Using 
TST with a cutoff size of >10 mm, followed by IGRA. In the model individuals go 
through the decision tree and end up in one of the Markov states, as detailed 
below.  
4.3.3.1 Model structure 
 We started with constructing a decision tree model for screening and 
treatment of LTBI using Tree-Age Pro2009 (TreeAge Software Inc, Williamstown, 
MA, USA) computer software. The model began with a decision between not 
screening for LTBI and screening with TST, or screening with IGRAs or 
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screening with TST followed by IGRAs (Figure 4.1 and Table 4.1). Whether they 
are screened or not screened, individuals either have LTBI or they do not; if they 
have LTBI, they have a risk of TB disease. In the screening arm of the model, a 
proportion of patients who tested positive for LTBI accepted to start treatment for 
LTBI and began INH therapy which was recommended for 9 months. If they 
began treatment, they either completed 9 months, completed only <6 months, 
completed 6–8 months, did not complete for drug toxicity, or did not complete for 
other reasons. For those who accepted therapy, model included an age-stratified 
risk of developing INH-induced hepatitis19 and for those who experienced 
hepatitis costs related to toxicity, decreased quality of life and increased risk of 
death were captured. Any individual who developed drug toxicity, either fatal INH 
induced hepatitis, or nonfatal hepatitis discontinued INH therapy. Individuals who 
refused the treatment did not begin INH and were followed for reactivation of 
LTBI.  
  Individuals who accepted INH-therapy and have not experienced an INH-
induced hepatitis also had a monthly probability of discontinuing therapy for 
reasons other than toxicity based on the literature13,20 and actual TBESC 
adherences rates to simulate the compliance.  
 Finally, Markov models were developed to trace and simulate the 
economic and clinical outcomes of screening and LTBI treatment for each 
screening strategy. Individuals move from one health state to another one in 
monthly cycles after completing treatment, taking an incomplete course or not 
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taking any treatment. They can develop active TB disease, get cured from TB, 
die from TB, die from drug toxicity, or die from another cause. Our model defined 
active TB as a 6-month period that had higher costs, higher mortality and 
decreased quality of life. At the end of 6-month-period, model assumed 
individuals who survived were back to well health state and had a normal life 
expectancy.  
3.3.3.2 Definition of variables 
Prevalence of LTBI 
 Prevalence of true LTBI status (versus prevalence of positive test results) 
was defined using TBESC data. Test validities used published estimates3,9,21,22 
with the following formula:  
Prevalence of positive test result = (test_sensitivity* prevalence of LTBI)+(1-
test_specificity)*(1- prevalence of LTBI) 
Prophylactic treatment for LTBI 
  TBESC participants who tested positive for LTBI and returned for their 
follow-up visit were modeled to use INH treatment for 9 months with incomplete 
treatments subgrouped as: 0–5 months, 6–8 months.7,13,23 While taking this 
treatment, adverse effects such as drug-related hepatitis, fatigue, fever, rash, etc. 
were recorded using standard questionnaires during 6-month follow-up visits. 
LTBI reactivation rate 
  We estimated the rate of reactivation TB in individuals with LTBI using the 
formula published by Horsburgh et al.24 Those who had a false positive testing 
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and did not have LTBI were not at risk for reactivation TB. We also accounted for 
self-cured LTBI and included a 10% reduction in the rate of reactivation over 
each decade.  
TB related mortality: 
 Patients with active TB had a 5% overall risk of death that we assumed 
uniformly spread throughout disease course. Those with underlying disease 
related with higher TB-related mortality had a 20% more risk of death from active 
TB.7,13 
 Mortality due to none-TB causes: 
 Mortality attributable to causes other than TB was a function of age and 
sex, and was adjusted to reflect differing competing risks of death between risk-
groups using life tables.25  
Costs:  
 Costs included direct medical costs and were expressed in 2014 U.S. 
dollars using Medical Expenditure Panel Survey and published reports of the 
healthcare costs in specific risk-groups (Table 3.2)13,17,26,27 The cost of IGRA 
screening included the cost of diagnostic kits, the cost of one nursing visit. The 
cost of TST screening included the cost of TST reagents, the cost of two nursing 
visits to cover initial placement and the read. The cost resulting from a positive 
screening test included one physician visit and one chest radiograph. The cost of 
INH prophylaxis per month on treatment included the costs of 30-day supply of 
INH 300 mg daily and one physician visit. For those who had nonfatal INH 
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induced hepatitis the costs included two physician visits and two sets of liver 
enzymes, whereas for those with fatal INH induced hepatitis cost of 
hospitalization was also added. The cost of active TB differed per months and 
included sputum smear testing and culture, contact tracing, TB hospitalization 
and drugs (INH, rifampin, pyrazinamide and ethambutol) for the first month. For 
the second month of active TB the costs include cost of drugs (INH, rifampin, 
pyrazinamide and ethambutol), daily direct observed therapy, one physician visit, 
chest radiograph, one set of liver enzymes. For the rest of the disease course for 
months 3 through 6, cost of active TB per each month on treatment included cost 
of drugs (INH and rifampin), direct observed therapy twice per week, one 
physician visit, one set of liver enzymes. During these months, the cost of one 
sputum smear testing and culture and one chest radiograph obtained at some 
point was also added. The cost of TB related mortality assumed 15 days of 
hospitalization and was also included in the model.  
 The model included direct healthcare costs expressed in 2014 US dollars. 
All costs were discounted at a fixed annual rate of 3%.28 Willingness to pay was 
set at both $50,000 per QALY gained and $100,000 per QALY gained thresholds 
to define screening as cost-effective. 29 
Effectiveness:  
 The main outcome measure of effectiveness was quality-adjusted life-years 
(QALY) which were based on published estimates collected using the Medical 
Outcomes Study SF-36 and the EQ-5D.30–32 We assumed that in the base case 
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scenario patients taking INH and did not experience toxicity had the same quality 
of life with the patients not taking INH.13,19,33 Sensitivity analyses were performed 
altering this assumption to include a decreased quality of life from using INH 
even without toxicity. Future benefits were discounted at an annual rate of 0.03. 
Utilities:  
 Health state utilities were based on published estimates using Short Form 
36 Health Survey and EuroQol dimensions (EQ-5D)30–32 and included weighting 
of 0.80 for active TB, for LTBI, and 1 got those with LTBI, those who survived 
active TB and those who had INH therapy without any adverse effects (Table 
3.3).  
4.3.3.2 Definition of outcomes 
Number needed to screen 
 We calculated the number needed to screen (NNS) to define the number of 
subjects screened to prevent one case of TB disease by dividing 1 by the 
absolute risk difference between strategies being compared 
Life time cost 
 Life time cost per person screened for each strategy was calculated by 
adding all direct medical costs collected in each health state on monthly bases.  
Life expectancy 
 Mean life expectancy per person screened was calculated for each 
screening strategy and compared to other strategies.  
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Incremental cost-effectiveness ratios 
 Incremental cost-effectiveness ratios (ICERs) calculated by dividing the 
difference between the sum of the costs for screening strategies and LTBI 
treatment being compared by the differences between the effectiveness of these 
screening strategies and LTBI treatment. Effectiveness in this context was 
measured in additional cost (in dollars) per quality adjusted year of life gained 
($/QALY). This means that the higher the ratio, the less cost-effective the 
intervention.  
4.3.3.3 Sensitivity analysis 
 In order to explore the role of uncertainty in main model parameters and to 
have a better insight in the factors driving the cost effectiveness of different LTBI 
screening strategies we conducted one-way and two-way sensitivity analyses by 
altering the value of all model parameters in their plausible ranges. We 
particularly evaluated the uncertainty in key model parameters such as rate of 
return for TST reading, mean age of patients, LTBI prevalence, rate of 
reactivation TB, TST and IGRA test characteristics and cost of IGRA. Poisson 
distribution and normal distribution were used to describe the uncertainty around 
the rate of reactivation TB and LTBI prevalence, respectively. Base case analysis 
was repeated by including three different estimates for reactivation TB rate: 0.11 
per 100 person-years (high estimate), 0.03 per 100 person-years (intermediate 
estimate) and 0.04 per 100 person-years (low estimate).47–49 We also conducted 
a series two-way sensitivity analyses by varying the test sensitivities and 
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specificities to evaluate how test characteristics impact the cost-effectiveness of 
each strategy. Finally, we performed a series of analyses including range of LTBI 
prevalence to understand the relationship between the LTBI prevalence and 
cost-effectiveness of screening strategies.  
4.4 RESULTS 
 
4.4.1 Base-case Analysis  
 Regardless of the assumptions and tests used, screening offers better 
health outcomes such as less TB cases and less TB related mortality compared 
to no screening (Table 4.6). Screening saves 2, 3, and 3 cases of TB per 1000 if 
TST to IGRA, TST alone and IGRA alone strategy is used, respectively. Applying 
the standard of care once an individual develops TB disease, for overall cohort 
our model estimates there will be 0.44 deaths per 1000 without any screening. 
With the different strategies used, expected annual deaths per 1000 are 0.31, 
0.29 and 0.28 for TST to IGRA, TST alone and IGRA alone, respectively. 
However, toxicity related deaths are not expected when no screening was done 
(Table 4.6). 
 Regardless of the assumptions and tests used, the screening program is 
always more costly than no screening in overall cohort and foreign-born 
individuals from different endemicity countries (Table 4.7).  In the base-case 
analysis, in overall group, compared to no screening, screening with TST 
followed with IGRA resulted in undiscounted life-expectancy gain of 0.0341 life-
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months (0.0110 discounted quality-adjusted life months) at an incremental cost of 
$85 ($197,993 discounted lifetime cost for TST to IGRA — $197,908 discounted 
lifetime cost for no screening). In overall group, compared to no screening, TST 
alone strategy resulted in undiscounted life-expectancy gain of 0.0399 life-
months (0.0110 discounted quality-adjusted life months) at an incremental cost of 
$165, and using IGRA resulted in undiscounted life-expectancy gain of 0.0433 
life-months (0.0139 discounted quality-adjusted life months) at an incremental 
cost of $202.  
 In the base-case scenario, in all groups evaluated, the screening strategy 
that involves using TST followed by IGRA testing among those who are found to 
be positive with TST was the most cost-effective screening algorithm (Figure 4.3 
and Table 4.7). In the overall group, the ICER of TST followed by IGRA 
compared to no screening was $75,094 per QALY gained. For TST alone and 
IGRA alone compared to no screening, ICERs were $127,164 and $140,632 per 
QALY, respectively.  
 In the base-case scenario, among foreign-born individuals, compared to 
no screening TST followed by IGRA resulted in undiscounted life-expectancy 
gain of 0.0415 life-months (0.0134 discounted quality-adjusted life months) at an 
incremental cost of $92 ($198,002 discounted lifetime cost for TST to IGRA — 
$197,910 discounted lifetime cost for no screening) and was the most cost-
effective strategy with a lowest cost per QALY gained ($66,784 per QALY) (Table 
  103 
3.7). When we stratified our analysis by country risk group, TST followed by 
IGRA remained as the most cost-effective strategy for LTBI screening among 
individuals who were born in high, moderate and low endemicity countries (Table 
3.7). 
4.4.2 Sensitivity Analysis 
 When we assumed different rates of reactivation TB, the ICERs for all 
screening strategies increased by decreasing reactivation rates but TST to IGRA 
remained as the most cost-effective algorithm (Table 4.8). At high rate of TB 
reactivation ICER of TST followed by IGRA was $30,160 per QALY gained, 
whereas at low rate of reactivation it increased up to $328,210 per QALY gained. 
Age of the patient affected cost-effectiveness results (Table 4.8). When we 
increased the mean age to 55 years, all strategies resulted in higher cost for 
QALY gained, and TST alone algorithm was dominated. In younger age groups, 
all strategies were more cost-effective compared to the older age groups, but 
TST to IGRA remained as the most cost-effective strategy in each age group 
tested. When we assumed that 100% of the patients returned for the read, using 
IGRA alone as a screening strategy was dominated by all other strategies. 
Similarly, when we assumed that cost of IGRA was 50% of the base-case, using 
TST alone algorithm was dominated by all other strategies. Screening with any of 
the algorithms remained cost-effective across all plausible estimates of test 
characteristics compared to no screening approach, and was less than $100,000 
per QALY gained across a wide range of assumptions about test characteristics 
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(Figure 4.5).  
4.5  DISCUSSION 
  
 Our study demonstrates that both in base-case scenario and sensitivity 
analysis, screening for LTBI was cost-effective, and improved health outcomes 
such as decreased number of TB cases, less TB related mortality, and increased 
life expectancy. The results of our model indicate that the TST followed by IGRA 
algorithm is the optimal approach for screening LTBI in individuals enrolled in 
TBESC. Sensitivity analyses suggest that the specificity of the TST and cost 
estimates of the IGRA have high impact on the algorithm choice, and should be 
subject to further research. The ultimate goal of LTBI screening programs is to 
prevent progression to active TB disease by early diagnosis and treatment. This 
analysis suggests that screening the 56,242 refugees that USA accepted in 2011 
would have prevented 170 cases of active TB cases in a year with a cost of $5 
million, and screening the 21 million foreign-born United States residents could 
prevent 63,000 cases with a cost of $1.8 billion additional cost compared to no 
screening.  
 Our results are in line with other studies comparing different screening 
strategies. Oxlade et al.35 compared TST and QFT in screening immigrants and 
contacts, found that a TST followed by QFT strategy is more cost effective than 
QFT single screening, particularly in a BCG vaccinated population. Diel et al.36 
concluded from a study comparing QFT assay and TST followed by QFT in 
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contacts in Switzerland that the dual strategy is more cost-effective than the QFT 
single strategy. These studies and our results agree with recommendations by 
National Institute of Health and Clinical Excellence (NICE, UK) which is using 
IGRAs in a dual testing strategy where IGRA is performed only on individuals 
who have a positive skin test. 
 
 There are studies with findings different to ours that support using a single 
IGRA testing strategy as being more cost-effective compared to dual 
testing.26,27,37 However, there are variations between these studies and our study 
in the assumptions regarding the test characteristics which potentially can 
explain different results. Kowada et al.37 in Japan assumed a lower sensitivity for 
both tests (76% for IGRA and 71% for TST). Perio et al.26 assumed higher 
sensitivity of IGRA with a perfect specificity for the QFT-IT (100%). It is both 
obvious and demonstrated that the superior specificity of an IGRA implies an 
important reduction in the number of persons treated unnecessarily for LTBI, the 
costs for the treatment of undetected active TB and the amount of LTBI that 
progresses to active TB, and higher sensitivities assumed in those models in the 
end will favor the IGRA-only strategy. 
 Our study has several caveats. Various assumptions had to be made 
regarding the test characteristics, reactivation rates, etc. and this limitation 
should be recognized when interpreting the results of the current study. First of 
all, there is no gold standard to confirm the diagnosis of LTBI. We used the best 
available surrogates and their estimated test characteristics; however, these are 
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inherently uncertain. Second, rate of reactivation TB is based on what is 
published in the literature with no long-term prospective observational data 
available. In the absence of any further data, however, we varied the rate of 
reactivation widely in our sensitivity analysis, and the TST to IGRA algorithm 
remained as the most cost-effective approach in the range tested.  
  In addition, the costs in the model include the direct medical costs, but not 
indirect costs such as loss of school days, loss of work days, transportation 
costs, etc. There are two main reasons for choosing this approach, although it is 
a limitation overall for the study. First of all, introducing such costs can generate 
ethical concerns mainly in vulnerable populations implying restrictions to their 
ability to work as they may be valued less than that of healthy and non-minority 
populations. Second, accurate assessment of such costs for a heterogeneous 
set of risk-groups is not feasible.  
  Also, our model does not include the secondary cases and wider 
transmission of TB into the community which would result in underestimation of 
the benefits of the screening methods. However, adding these parameters and 
dynamics to the decision tree would make the model more complicated, and the 
number of secondary cases that would be prevented is likely to be quite small.  
  Finally, comparing the ICERs estimated from our model to other studies 
can be hampered by the country specific parameters such as currencies, 
manufacturer’s costs at the specific country, the costs for manpower to perform 
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the testing, costs for CXRs, chemoprevention and costs for hepatitis developed 
during INH treatment. 
 Despite these limitations, the results of our economic analysis suggest 
that screening is attractive mostly because the costs of the tests available are not 
very high, and it avoids higher costs associated with treatment of active TB 
disease. For comparison, it has been estimated that the incremental cost per 
QALY gained for treating hypertension can be as high as $490,00038, and the 
ICER of breast MRI compared to mammography among young women at high 
risk can be $179,599/QALY.39  
 Economic analysis and cost-effectiveness are crucial pieces to be 
considered in decision making in healthcare. Policy makers should prioritize 
groups for targeted LTBI screening such as foreign-born individuals, and 
consider using TST followed by IGRA to improve the efficiency of the screening 
program which will maximize the impact of public health resources allocated to 
eradicate TB in the USA. Our study is unique in that it was performed among 
individuals who came from moderate to high-incidence countries who are 
currently living in a high-income, low-incidence country. It remains to be seen 
whether these findings will be confirmed in high-incidence and resource-limited 
settings 
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4.7 TABLES  
 
Tables 4.1. Select input parameters used in cost-effectiveness model of 
screening strategies for latent tuberculosis  
Variable Base case 
value
Range 
evaluated
Source
Demographic
Age, year 27
Female (%) 0.48 TBESC
TST positivity 0.39 TBESC
Test characteristics
TSTsensitivity 0.89 (3, 13)
TST specificity 0.92 (3, 13)
IGRA sensitivity 0.83 (3, 13)
IGRA specificity 0.99 (3, 13)
TB reactivation rate per 100 person years 0.079 (7, 13, 24)
Probability of return for read 0.88 (11, 13, 14)
Probability of starting treatment 0.9 (13, 14)
Probability of completing treatment 0.51 TBESC, (13, 20)
Treatment effectiveness
<6 months 0.3 (7, 13, 23)
6-8 months 0.6 (7, 13, 23)
9 months 0.9 (7, 13, 23)
Probability of INH related hepatotoxicity 0.01 (13, 19, 34)
Probability of fatal INH-related hepatitis 0.0001 (13, 19, 34)
Probability of death given active TB
No comorbidities 0.05 (7, 13)
With comorbidities 0.06 (7, 13) 
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Table 4.2. Medication and hospital cost (per case) used in cost-effectiveness 
model of screening strategies for latent tuberculosis 
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Table 4.3. Utilities included in the cost-effectiveness model for screening 
strategies for latent tuberculosis 
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Table 4.4. Population characteristics 
Characterisictis n %*
Age, years (mean, + sd)
n %
Female 4812 46.7
Foreign-born 8382 81.4
Country of birth
Low endemicity (<125) 2925 34.9
Moderate endemicity (<125-299) 3487 41.6
High endemicity (>=300) 1964 23.5
HIV 1345 13.2
Renal failure 64 0.6
Diabetes 524 5.1
Steroid use 143 6.1
Transplant 18 0.2
TNF-alpha use 15 0.6
Pregnancy 150 3.8
Holding center 2938 28.7
Correctional facility 1046 11.9
Homeless 795 7.8
Drug facility 625 7.1
Long term facility 605 5.9
Smoked >100 packs in the past 2822 34.1
Current smoker 1790 63.6
Alcohol use
Never 5118 62.13
Once a month or less 1611 19.56
2-3 times a month 573 6.96
Once per week 372 4.52
2-3 times a week 402 4.88
4 or more times a week 161 1.95
Recreational drug use 1394 16.9
Intravenous drug use 429 31
32.1 (17.5)
*Totals are different due to missing data
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Table 4.5. Select input parameters used on cost-effectiveness model of 
screening strategies for latent tuberculosis 
 
N % N % N % N %
Overall 4026 39.1 6273 60.9 1946 18.9 8353 81.1
Foreign-born 3836 45.8 4546 54.2 1815 21.7 6567 78.3
USA-born 190 9.9 1727 90.1 131 6.8 1786 93.2
Counrty of birth
Low endemicity (<125) 1084 37.1 1841 62.9 428 14.6 2497 8534
Moderate endemicity (<125-299) 1765 50.6 1722 49.4 948 27.2 2539 72.8
High endemicity (>=300) 984 50.1 980 49.9 437 22.3 1527 77.7
Positive Negative
TST IGRA
Positive Negative
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Table 4.6. Base case results of cost-effectiveness model of screening strategies for latent tuberculosis  
n %
No testing 0.008746792 - 0.000435493 0
TST to IGRA 0.006265382 403 2 0.000311941 0.0000222
TST Alone 0.005757141 334 3 0.000286635 0.0000305
IGRA Alone 0.005578495 316 3 0.00027774 0.0000288
No testing 0.010623316 0.000528923 0
TST to IGRA 0.007609547 332 3 0.000378864 0.0000269
TST Alone 0.006992269 275 4 0.000348129 0.0000357
IGRA Alone 0.006775296 260 4 0.000337326 0.0000348
No testing 0.011844322 0.000589716 0
TST to IGRA 0.008484161 298 3 0.000422409 0.0000300
TST Alone 0.007795935 247 4 0.000388142 0.0000391
IGRA Alone 0.007554025 233 4 0.000376097 0.0000387
No testing 0.011990617 0.000597 0
TST to IGRA 0.008588953 294 3 0.000427627 0.0000304
TST Alone 0.007892227 244 4 0.000392936 0.0000395
IGRA Alone 0.007647328 230 4 0.000380742 0.0000391
No testing 0.008175677 0.000407058 0
TST to IGRA 0.005856288 431 2 0.000291573 0.0000207
TST Alone 0.005381232 358 3 0.000267919 0.0000289
IGRA Alone 0.005214251 338 3 0.000259605 0.0000270
Avoided 
TB cases 
per 1000
39.09 0.079
Group
Reactivation 
rate (per 100 
person 
years)
Strategy
Observed TST 
positivity in TBESC
4026 /10299Overall
Number 
needed 
to screen
TB cases TB Death Toxicity deaths
50.62 0.079
Foreign-born 3836 /8382 45.76 0.079
Low endemicity in 
counrty of birth 1084 / 2925 37.06 0.079
High endemicity in 
counrty of birth 984 / 1964 50.1 0.079
Moderate 
endemicity in 
counrty of birth
1765 / 3487
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Table 4.7. Cost effectiveness of different screening strategies for latent tuberculosis 
 
 
 
No testing 197,908.00 - - - 629.55 311.65
TST to IGRA 197,993.00 0.0136 6257.8845 75,094.61 629.59 311.66
TST Alone 198,073.00 0.0155 10597.0672 127,164.81 629.59 311.66
IGRA Alone 198,110.00 0.0172 11719.3948 140,632.74 629.60 311.66
No testing 197,910.00 - - - 629.52 311.64
TST to IGRA 198,002.00 0.0165 5,565.34 66,784.10 629.56 311.65
TST Alone 198,096.00 0.0192 9,695.32 116,343.84 629.57 311.65
IGRA Alone 198,136.00 0.0209 10,793.54 129,522.46 629.57 311.65
No testing 197,912.00 - - - 629.49 311.63
TST to IGRA 198,008.00 0.0184 5,232.65 62,791.82 629.54 311.64
TST Alone 198,111.00 0.0215 9,271.30 111,255.59 629.55 311.64
IGRA Alone 198,154.00 0.0234 10,349.90 124,198.80 629.55 311.65
No testing 197,912.00 - - - 629.49 311.63
TST to IGRA 198,009.00 0.0186 5,197.34 62,368.07 629.54 311.64
TST Alone 198,113.00 0.0218 9,226.63 110,719.60 629.55 311.64
IGRA Alone 198,156.00 0.0237 10,302.85 123,634.25 629.55 311.64
No testing 197,907.00 - - - 629.57 311.65
TST to IGRA 197,990.00 0.0127 6,531.82 78,381.90 629.60 311.66
TST Alone 198,066.00 0.0144 10,961.07 131,532.87 629.60 311.66
IGRA Alone 198,101.00 0.0161 12,086.51 145,038.08 629.61 311.67
Moderate 
endemicity in 
counrty of birth
Low endemicity in 
counrty of birth
Foreign-born 
High endemicity in 
counrty of birth
Undiscounted 
per person 
life 
expectancy 
(months)
Discounted 
quality-adjusted 
life expectancy 
(QALM)
Overall
Discounted 
per person 
lifetime cost 
($)
Incrementa
l Value
Incremental 
cost-
effectiveness 
ratio ($/QALM)
Incremental 
cost-
effectiveness 
ratio ($/QALY)
Group Strategy
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Table 4.8. Sensitivity analysis of the incremental cost-effectiveness ratio (ICER) 
for latent tuberculosis infection 
Parameter Strategy Base-case
0.079 per 100 PY 0.04 per 100 PY 0.11 per 100 PY
TST to IGRA 75,094 328,210 30,160
Rate of reactivation TST Alone 127,164 417,705 81,448
IGRA Alone 140,634 420,824 91,570
27 yo 15 yo 55 yo
TST to IGRA 75,094 72,195 202,352
Age TST Alone 127,164 464,512 779,178
IGRA Alone 140,634 258,283 542,780
0.88 0.5 1
TST to IGRA 75,094 89,861 72,662
Return for TST read TST Alone 127,164 Dominated 125,029
IGRA Alone 140,634 140,537 Dominated
$51 $26 $104
TST to IGRA 75,094 57,248 80,988
Cost of IGRA TST Alone 127,164 Dominated 127,074
IGRA Alone 140,634 127,074 154,225
Sensitivity analysis
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4.8 FIGURES  
 
Figure 4.1. Study flow diagram  
Approached (n=14,673)
Enrolled (n=12,134 [82.7%])
Declined (n=2,539 [17.3%])
n=11,940 [98.4%]
Reason for enrollment:
• Close contact (n=1212 [10.2%])
• Foreign-born from high-risk country (n=6551 
[54.9%])
• Foreign-born from medium-risk country who moved 
to US within the past 5 years (n=2195 [18.4%])
• Spent at least 30 days in high risk country in last 5 
years (n=98 [0.8%])
• HIV-positive (n=1326 [11.1%])
• Member of a group with LTBI prevalence >25% 
(n=553 [4.6%])
• Unknown (n=5 [0.0%])
Excluded from dataset (n=194 [1.6%])
• Ineligible, mistakenly enrolled (n=39 [20.1%])
• Diagnosed with TB during screening (n=36 [18.6%])
• Contact of Mtb-negative source case (n=20 [10.3%])
• Invalid results for all 3 tests (n=99 [51.0%])
Analysed those with valid results for TST, QFT, TSPOT (n=10,299 [86.3%])
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Figure 4.2. Decision tree structure for cost-effectiveness analysis of LTBI 
screening and treatment 
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Figure 4.2. Decision tree structure for cost-effectiveness analysis of LTBI 
screening and treatment (continued) 
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Figure 4.3. Markov structure for cost-effectiveness analysis of LTBI screening 
and treatment 
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Figure 4.4. Cost-effectiveness of different screening strategies for latent tuberculosis in TBESC participants 
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Figure 4.5. Two-way sensitivity analysis of the incremental cost-effectiveness 
ratio of screening for latent tuberculosis infection. The figure depicts the choice of 
screening strategy at willingness to pay $100,000 per quality adjusted life-year 
gained.  
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5. CONCLUSIONS 
 
 Over the last two centuries since first vaccine was developed, 
epidemiology of infectious diseases has evolved, and ongoing surveillance is 
warranted to identify evaluate the impact of vaccines provided.1–4 This 
dissertation explored the impact of 13-valent pneumococcal conjugate vaccine 
on all-cause pneumonia burden (study 1), the association between Bacille 
Calmette Guérin (BCG) vaccine on tuberculin skin testing (TST) (study 2), and 
the cost-effectiveness of different screening strategies for latent tuberculosis 
infection (LTBI) (study 3).  
 Streptococcus pneumoniae is recognized as the primary bacterial 
pathogen of pneumonia in all age groups.5,6 Conjugated pneumococcal vaccine 
(PCV) provides immunity against S pneumoniae, and the first generation PCV 
which included seven serotypes has been reported to have impact on all-cause 
pneumonia disease burden.6,7 A second generation, 13-valent conjugate vaccine 
(PCV13) targeting six additional serotypes that were not included in prior 
conjugated vaccine was introduced in 2010.8 Because serotypes 1, 3, 7F, and 
19A were the most predominant in documented pneumococcal pneumonia in 
children, and these serotypes were included in PCV13, a strong additional impact 
of this new PCV on the disease burden was expected but not yet demonstrated. 
In addition, despite broad vaccine uptake bacterial pneumonia remains 
disproportionately more frequent in urban, minority children including greater 
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morbidity and mortality.6,9 The impact of PCV13 in this specific population is 
known and we need further understanding in order to optimize the health 
outcomes in this vulnerable group. 
Tuberculosis (TB) is a worldwide public health problem caused by 
Mycobacterium tuberculosis (MTb).10–12 Reactivation of dormant bacteria in 
individuals with LTBI accounts for the majority of active tuberculosis cases, and 
thus any successful tuberculosis prevention and control program targets 
identification and treatment of persons with LTBI who are at the highest risk of 
progression to active TB disease.12–14 Currently, two screening modalities are 
widely accepted for use in diagnosing LTBI: interferon-gamma release assays 
(IGRAs) and TST.15,16 Two FDA-approved IGRAs are available in the United 
States are the QuantiFERON-TB Gold In-Tube (QFT) and the T-SPOT.TB (T-
Spot). IGRAs are moe expensive, 17 In addition, TST results are reported to be 
less specific among individuals who had received BCG vaccination,18,19 and 
might lead to false positive results which will contribute to treatment of individuals 
without LTBI with increased health cost and possible toxicity from the treatment 
regimen. Screening with using IGRAs include has its own caveats though. First 
they are relatively expensive compared to TST.11 They also require a laboratory 
infrastructure and the is lack of consensus on how to define and interpret 
conversions, reversions and nonspecific variations that occur with IGRA serial 
testing.11,15 Taking all these into consideration, WHO does not advise using 
IGRAs in low- and middle-income countries with high disease burden, however 
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further research is needed to develop most effective screening strategies in 
settings with low disease burden and high income such as United States.20  
 In study 1, we used a large electronic health record data, Massachusetts 
Health Disparities Repository (MHDR), to evaluate the impact of PCV13 on all-
cause pneumonia among children who receive primary care at Boston Medical 
Center (BMC). We extracted all-cause pneumonia cases diagnosed at both 
inpatient and outpatient settings among children younger than 8 years of age. 
Using interrupted time-series regression analysis monthly rates were estimated 
for years after (2011–2013) implementation of PCV13 were compared to 
expected rates calculated from pre-PCV13 era (2007–2009). The year of PCV13 
introduction (2010) was excluded.  We also extracted cases of urinary tract 
infection as control outcome. At the end of 2013 compared to prePCV13 era, 
among children younger than 2 years of age there was a 35.3% (95% CI 5.4–
65.3) reduction in all-cause pneumonia cases. In children with comorbidity, 
pneumonia declined by 38.8% (95% CI 11.1 to 65.4) in those younger than 2 
years of age, and 28.7% (95% CI 2.9 to 54.5) in those 2 to 8 years of age. The 
results of this study contribute to the growing body of evidence supporting the 
benefit of indirect protection with conjugated vaccines, and emphasize the 
importance of high sustainable vaccine coverage rates.  
 In study 2, the association between BCG vaccination and TST positivity 
was evaluated using data from the Tuberculosis Epidemiologic Studies 
Consortium (TBESC) Study-1, a 10-site collaboration of academic institutions, 
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and state and local TB control programs in United States. Prior BCG vaccination 
had no impact on the TST results once adjusted for history of household contacts 
(adjusted PR 1.0, 95% CI 0.4–1.5). The results of this study add further evidence 
that BCG vaccination has little impact on TST results in children, particularly in 
older age groups. 
In study 3, again using the TBESC Study-1 data, we examined the cost-
effectiveness of three different screening strategies compared to no screening for 
LTBI in a population with high proportion of foreign-born individuals. We 
compared four different algorithms for LTBI screening: TST only, IGRA only, TST 
followed by IGRA among those who were TST positive, and no screening. 
Regardless of the assumptions and tests used, screening provided better health 
outcomes such as less TB cases and less TB related mortality compared to no 
screening. The dual-step algorithm that involves TST followed by IGRA was 
found to be the most cost-effective strategy.  This study contributes to the 
accumulating evidence in the literature supporting prioritizing certain groups for 
targeted LTBI screening such as foreign-born individuals, and using TST 
followed by IGRA to maximize the impact of public health resources allocated to 
eradicate TB in the United States.  
In all three studies, there were some reoccurring methodological issues 
that we encountered, and should be considered when interpreting the results. 
First, the exposure and the confounder information collected retrospectively 
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using medical records or questionnaires. We cannot rule out the possibility of 
misclassification as we relied on international disease classification codes in the 
charts, or self-report of vaccine and TB exposure history, etc. We do not think 
this will lead to recall bias though, since the information on exposure such as 
prior BCG vaccine was collected before the outcome i.e. TST results was known. 
Confounding and residual confounding were of concern for all of the three 
studies, and although we made every attempt to control for confounding we 
cannot rule out residual confounding. In addition, our study populations are very 
specific such as urban children seeking medical care in one center in Boston, MA 
or foreign-born individuals with high likelihood to be exposed to an active TB 
case in the past. Thus, our results may not be generalizable to many other 
populations such as individuals form low TB prevalence settings. Also for the 
third study, our model included various assumptions made regarding the test 
characteristics, reactivation rates, etc. and this limitation should be recognized 
when interpreting the results. 
From the public health perspective, the findings from these three studies 
have significant implications. The results of the first study suggest that PCV13 
lead to reduction in all-cause pneumonia rates not only among targeted age 
groups but all nonvaccinees, and children with comorbidities experienced a 
bigger protection which emphasizes the importance of improving vaccine 
coverage to decrease preventable childhood mortality and morbidity. The 
findings the second study that a 'positive' TST response to past BCG vaccination 
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may be encouraging a false sense of security among children with history of 
exposure to an infectious case of TB, and that interpretation of TST should be 
made in the individual clinical and risk context. Finally, results of the third study 
suggest that using TST followed by IGRA for LTBI screening in targeted 
populations such as foreign-born individuals is cost-effective, and can improve 
the outcomes of TB control program in the United States. Overall, our findings 
contribute to the further understanding of the impact of the vaccines and the 
changing epidemiology of vaccine-preventable diseases and provide more 
insight to formulate new strategies to improve overall health of children. 
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